<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Oseltamivir</title><meta name="description" content="Oseltamivir is an oral antiviral prodrug indicated for the treatment of acute uncomplicated influenza A and B infections in patients two weeks of age and older who have been symptomatic for no more than two days, as well as for post-exposure prophylaxis in individuals one year and older. Developed by Gilead Sciences and marketed by Roche under the brand name Tamiflu, it functions as a neuraminidase inhibitor; after hydrolysis in the liver to its active carboxylate metabolite, this compound..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="Tamiflu"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Oseltamivir"/><meta property="og:title" content="Oseltamivir"/><meta property="og:description" content="Oseltamivir is an oral antiviral prodrug indicated for the treatment of acute uncomplicated influenza A and B infections in patients two weeks of age and older who have been symptomatic for no more than two days, as well as for post-exposure prophylaxis in individuals one year and older. Developed by Gilead Sciences and marketed by Roche under the brand name Tamiflu, it functions as a neuraminidase inhibitor; after hydrolysis in the liver to its active carboxylate metabolite, this compound..."/><meta property="og:url" content="https://grokipedia.com/page/Oseltamivir"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Oseltamivir"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:45.937Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Oseltamivir"/><meta name="twitter:description" content="Oseltamivir is an oral antiviral prodrug indicated for the treatment of acute uncomplicated influenza A and B infections in patients two weeks of age and older who have been symptomatic for no more than two days, as well as for post-exposure prophylaxis in individuals one year and older. Developed by Gilead Sciences and marketed by Roche under the brand name Tamiflu, it functions as a neuraminidase inhibitor; after hydrolysis in the liver to its active carboxylate metabolite, this compound..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="c36aaaff0956af7333c121f3defab1c8-39f612134c3e497b-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=c36aaaff0956af7333c121f3defab1c8,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.1359057202668128,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#oseltamivir" class="transition-opacity hover:opacity-100 opacity-50">Oseltamivir</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacology" class="transition-opacity hover:opacity-100 opacity-50">Pharmacology</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mechanism-of-action" class="transition-opacity hover:opacity-100 opacity-50">Mechanism of Action</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacokinetics" class="transition-opacity hover:opacity-100 opacity-50">Pharmacokinetics</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-uses" class="transition-opacity hover:opacity-100 opacity-50">Clinical Uses</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#treatment-indications" class="transition-opacity hover:opacity-100 opacity-50">Treatment Indications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#prophylaxis-applications" class="transition-opacity hover:opacity-100 opacity-50">Prophylaxis Applications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#use-in-special-populations" class="transition-opacity hover:opacity-100 opacity-50">Use in Special Populations</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#efficacy-and-evidence" class="transition-opacity hover:opacity-100 opacity-50">Efficacy and Evidence</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#seasonal-influenza-outcomes" class="transition-opacity hover:opacity-100 opacity-50">Seasonal Influenza Outcomes</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pandemic-and-high-risk-scenarios" class="transition-opacity hover:opacity-100 opacity-50">Pandemic and High-Risk Scenarios</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#meta-analyses-and-controversies" class="transition-opacity hover:opacity-100 opacity-50">Meta-Analyses and Controversies</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#safety-and-adverse-effects" class="transition-opacity hover:opacity-100 opacity-50">Safety and Adverse Effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#common-side-effects" class="transition-opacity hover:opacity-100 opacity-50">Common Side Effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#serious-risks-and-warnings" class="transition-opacity hover:opacity-100 opacity-50">Serious Risks and Warnings</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#neuropsychiatric-concerns" class="transition-opacity hover:opacity-100 opacity-50">Neuropsychiatric Concerns</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#resistance" class="transition-opacity hover:opacity-100 opacity-50">Resistance</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mechanisms-of-resistance" class="transition-opacity hover:opacity-100 opacity-50">Mechanisms of Resistance</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#prevalence-across-influenza-strains" class="transition-opacity hover:opacity-100 opacity-50">Prevalence Across Influenza Strains</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-implications" class="transition-opacity hover:opacity-100 opacity-50">Clinical Implications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history-and-development" class="transition-opacity hover:opacity-100 opacity-50">History and Development</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#discovery-and-early-research" class="transition-opacity hover:opacity-100 opacity-50">Discovery and Early Research</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#regulatory-approval-and-key-trials" class="transition-opacity hover:opacity-100 opacity-50">Regulatory Approval and Key Trials</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#data-transparency-and-policy-debates" class="transition-opacity hover:opacity-100 opacity-50">Data Transparency and Policy Debates</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#non-human-applications" class="transition-opacity hover:opacity-100 opacity-50">Non-Human Applications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#veterinary-use" class="transition-opacity hover:opacity-100 opacity-50">Veterinary Use</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#current-research-and-alternatives" class="transition-opacity hover:opacity-100 opacity-50">Current Research and Alternatives</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#emerging-studies" class="transition-opacity hover:opacity-100 opacity-50">Emerging Studies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#comparative-antivirals" class="transition-opacity hover:opacity-100 opacity-50">Comparative Antivirals</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="oseltamivir" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Oseltamivir<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><br/>
Oseltamivir is an oral antiviral prodrug indicated for the treatment of acute uncomplicated influenza A and B infections in patients two weeks of age and older who have been symptomatic for no more than two days, as well as for post-exposure prophylaxis in individuals one year and older.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_80qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Developed by Gilead Sciences and marketed by Roche under the brand name Tamiflu, it functions as a neuraminidase inhibitor; after hydrolysis in the liver to its active carboxylate metabolite, this compound competitively binds to the active site of the viral neuraminidase enzyme, thereby inhibiting the cleavage of sialic acid residues on host cells and preventing the release of progeny virions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Clinical trials and meta-analyses have demonstrated that oseltamivir shortens the median duration of influenza symptoms by approximately 12 to 29 hours in adults and children, respectively, compared to placebo, though benefits on preventing complications such as lower respiratory tract infections or hospitalization appear limited in otherwise healthy outpatients.62449-1/abstract)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> In hospitalized patients with severe influenza, however, treatment has been associated with reduced mortality and shorter hospital stays, particularly when initiated early.01307-2/fulltext)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> The drug&#x27;s efficacy is most pronounced against susceptible strains, but resistance can emerge, as observed in seasonal H1N1 variants during widespread use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Oseltamivir has faced scrutiny over its modest clinical impact relative to high stockpiling costs during pandemics like H1N1 in 2009, with independent reviews revealing that manufacturer-held trial data overstated benefits on complications and transmission, leading to questions about regulatory reliance on incomplete submissions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Common adverse effects include nausea and vomiting in up to 10% of users, while rare but serious neuropsychiatric eventsâ€”such as delirium, hallucinations, and self-harmâ€”have been reported, disproportionately in pediatric populations, prompting warnings for behavioral monitoring.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Despite these concerns, it remains a cornerstone of influenza management in high-risk groups due to limited alternatives.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<h2 id="pharmacology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pharmacology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="mechanism-of-action" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Mechanism of Action<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Oseltamivir is an ethyl ester prodrug rapidly hydrolyzed by endogenous carboxylesterases, primarily in the liver, to its active metabolite oseltamivir carboxylate, which exerts the antiviral effect.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_63abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Oseltamivir carboxylate functions as a competitive inhibitor of the neuraminidase (NA) enzyme, a surface glycoprotein unique to influenza A and B viruses that is essential for viral replication.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The NA enzyme cleaves terminal sialic acid residues linked by Î±-2,3 or Î±-2,6 glycosidic bonds to oligosaccharides on the host cell surface and viral glycoproteins, enabling the release of progeny virions from infected cells and preventing their aggregation via multivalent sialic acid interactions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_63qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> Oseltamivir carboxylate binds tightly to the enzyme&#x27;s active site, mimicking the planar oxocarbonium ion transition state of sialic acid during hydrolysis, with the inhibitor&#x27;s carboxylate group forming ionic interactions and its hydrophobic pentyloxy substituent occupying a conserved pocket adjacent to the sialic acid-binding region.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> This binding inhibits NA activity, trapping virions on the host cell surface and limiting cell-to-cell spread within the respiratory tract.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Enzymatic inhibition assays demonstrate high potency against influenza A and B NAs, with IC<sub>50</sub> values for oseltamivir carboxylate typically in the low nanomolar range (e.g., 1.4â€“3.7 nM across susceptible strains), reflecting its structural optimization as a transition-state analog.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> The inhibitor exhibits specificity for viral NAs, showing negligible activity against mammalian sialidases or those from non-influenza viruses due to differences in active site architecture.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">X-ray crystallographic analyses of NA-oseltamivir carboxylate complexes confirm the molecular basis of inhibition, revealing hydrogen bonds between the inhibitor&#x27;s functional groups and conserved arginine residues (e.g., Arg118, Arg292, Arg371) in the active site, alongside van der Waals contacts that stabilize the enzyme-inhibitor complex across influenza subtypes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_64qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> These interactions underscore the drug&#x27;s design, derived from sialic acid analogs, to exploit the catalytic mechanism of NA without affecting host enzymes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<h3 id="pharmacokinetics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pharmacokinetics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Oseltamivir phosphate, the prodrug form of oseltamivir, is administered orally and readily absorbed from the gastrointestinal tract, with at least 75% of the dose systemically available as the active metabolite oseltamivir carboxylate following rapid hydrolysis by hepatic esterases; less than 5% circulates as unchanged prodrug. Plasma concentrations of oseltamivir carboxylate are proportional to dose and exhibit high bioavailability unaffected by concomitant food intake, with peak levels typically attained 3 to 4 hours post-administration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_65qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The apparent elimination half-life of oseltamivir is 1 to 3 hours, whereas oseltamivir carboxylate persists longer with a half-life of 6 to 10 hours. Elimination of the active metabolite occurs almost entirely via renal excretion (&gt;90% of dose recovered in urine), involving glomerular filtration and active tubular secretion, as indicated by its renal clearance of 18.8 L/h exceeding the glomerular filtration rate of 7.5 L/h.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The volume of distribution for oseltamivir carboxylate is 23 to 26 L, with minimal plasma protein binding (~3%), reflecting limited tissue distribution. Due to its low lipophilicity and polarity, oseltamivir carboxylate demonstrates restricted penetration across the blood-brain barrier.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> In patients with renal impairment, accumulation of oseltamivir carboxylate occurs with declining creatinine clearance, requiring dosage reductions such as 30 mg twice daily for treatment in those with clearance of 30 to 60 mL/min.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<h2 id="clinical-uses" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Clinical Uses<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="treatment-indications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Treatment Indications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Oseltamivir is approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute uncomplicated influenza in patients two weeks of age and older who have been symptomatic for no more than 48 hours, targeting influenza A and B viruses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> The European Medicines Agency (EMA) authorizes its use for treating influenza in adults and children one year of age or older presenting with typical symptoms, when influenza is circulating in the community, with extensions to full-term newborns in certain contexts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> These indications stem from randomized controlled trials showing oseltamivir shortens the duration of symptoms and reduces viral shedding compared to placebo.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Pivotal clinical trials, as synthesized in the 2009 Cochrane review by Jefferson et al., demonstrated that oseltamivir reduces the time to alleviation of influenza symptoms by approximately 1 day (29 hours) in adults with laboratory-confirmed cases when initiated within 48 hours of onset.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> In children, similar trials reported a reduction of about 0.8 days in symptom duration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_88qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> Oseltamivir also decreases the duration of viral shedding by 1 to 2 days, limiting infectiousness, based on virological endpoints from these studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The Centers for Disease Control and Prevention (CDC) recommends oseltamivir for treating influenza in outpatients with uncomplicated illness, emphasizing initiation as soon as possible, ideally within 48 hours, to achieve these benefits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> For hospitalized patients or those with severe or complicated influenza, CDC guidelines endorse oseltamivir regardless of symptom duration, with evidence from observational data and trials indicating modest reductions in complications like pneumonia in high-risk groups such as the elderly or those with comorbidities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> The World Health Organization (WHO) similarly advises oseltamivir for severe influenza cases, prioritizing empirical outcomes in resource-variable settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Since the expiration of key patents in 2016, generic oseltamivir has become widely available, lowering costs and enhancing treatment access in low- and middle-income countries where branded formulations were prohibitive.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> This shift has supported broader deployment during seasonal outbreaks without compromising the drug&#x27;s established dosing regimen of 75 mg twice daily for 5 days in adults.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
<h3 id="prophylaxis-applications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Prophylaxis Applications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Oseltamivir is approved for post-exposure prophylaxis (PEP) against influenza A and B viruses when administered within 48 hours of exposure to a confirmed case, particularly in household settings where transmission risk is elevated.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> Randomized controlled trials have demonstrated protective efficacy ranging from 70% to 89% against symptomatic influenza illness in household contacts, with one double-blind study of 457 contacts reporting an 89% reduction (95% CI, 67%-96%) in clinical influenza when oseltamivir was given as 75 mg once daily for 7 to 10 days.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> These protocols emphasize short-term administration, typically 10 days, to target immediate transmission prevention while aligning with trial durations that confirmed efficacy without extending exposure to unnecessary selective pressure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For adults and adolescents aged 13 years and older, the standard PEP regimen is 75 mg orally once daily for at least 10 days, adjustable based on renal function (e.g., reduced to 75 mg every other day for creatinine clearance 10-30 mL/min).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> Seasonal prophylaxis applications include use during community outbreaks or in institutional settings, such as nursing homes, where oseltamivir has shown reductions in influenza incidence when initiated early, though evidence derives primarily from targeted rather than broad implementation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ababav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> However, large-scale community-wide prophylaxis strategies, including stockpiling for pandemic scenarios like the 2009 H1N1 outbreak, have demonstrated limited causal impact on overall transmission at the population level, as global spread persisted despite distribution of over 220 million courses across multiple countries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ebabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In immunocompromised individuals, such as transplant recipients, oseltamivir prophylaxis reduces culture- or PCR-confirmed influenza incidence (e.g., from 5.4% to 1.6% in one randomized trial), but breakthrough infections occur at higher rates than in immunocompetent populations, necessitating individualized assessment and often combination with vaccination or monitoring for resistance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> Guidelines recommend its use in high-risk exposure scenarios for this group, though efficacy data highlight incomplete protection, with some studies reporting persistent viral shedding despite prophylaxis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<h3 id="use-in-special-populations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Use in Special Populations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Oseltamivir is approved by the U.S. Food and Drug Administration for the treatment of acute uncomplicated influenza in pediatric patients aged 1 year and older, with dosing determined by body weight: for children weighing less than 15 kg, the recommended dose is 30 mg orally twice daily for 5 days; for 15 to 22.9 kg, 45 mg twice daily; for 23 to 40 kg, 60 mg twice daily; and for those over 40 kg, 75 mg twice daily. Clinical trials in children aged 1 to 12 years demonstrated a reduction in the median time to symptom alleviation by approximately 21 to 29 hours compared to placebo when initiated within 48 hours of symptom onset.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> However, vomiting occurs more frequently in this population, affecting about 16% of treated children aged 1 to 12 years versus 8% in placebo groups, though this adverse effect is generally self-limited and does not typically necessitate discontinuation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Use in infants under 1 year remains off-label due to insufficient safety and efficacy data from controlled trials, although the American Academy of Pediatrics suggests weight-based dosing (e.g., 3 mg/kg twice daily for those under 3 months in severe cases) based on observational evidence of potential benefit in hospitalized neonates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ccqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In pregnant women, oseltamivir carries an FDA Pregnancy Category C designation, indicating that animal reproduction studies have not shown adverse effects but adequate human studies are lacking, necessitating a risk-benefit assessment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> The Centers for Disease Control and Prevention recommend prompt initiation for suspected or confirmed influenza, particularly in cases of severe illness or hospitalization, supported by observational studies from registries like the U.S. Pregnancy Risk Assessment Monitoring System showing reduced maternal hospitalization rates (odds ratio 0.44) and lower risks of preterm birth or fetal loss when treated early.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> Limited randomized controlled trials exist due to ethical constraints, but post-marketing surveillance data through 2024, including over 1,000 exposures, report no consistent signals of teratogenicity or fetal harm.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> The standard adult dose of 75 mg twice daily for 5 days is used without adjustment, and breastfeeding is considered compatible given minimal drug transfer into breast milk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For elderly patients and those with high-risk comorbidities (e.g., chronic pulmonary or cardiovascular disease), oseltamivir is recommended within 48 hours of symptom onset to mitigate progression, with real-world cohort studies indicating reduced odds of hospitalization; for instance, a 2025 analysis in <em>JAMA Network Open</em> of over 10,000 hospitalized influenza cases found early treatment associated with a 25% lower risk of intensive care admission in older adults aged 65 and above. Subgroup analyses from propensity-matched observational data further show shortened hospital stays (by 1-2 days) and decreased 30-day readmission rates in this demographic.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> Nonetheless, meta-analyses of randomized trials reveal no significant mortality benefit in all elderly subgroups, with hazard ratios around 0.90-1.00 for death, particularly absent in non-hospitalized or low-risk elderly where evidence gaps persist due to underrepresentation in pivotal studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> Dosing remains 75 mg twice daily unless renal impairment requires adjustment (e.g., 75 mg once daily for creatinine clearance 30-60 mL/min).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<h2 id="efficacy-and-evidence" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Efficacy and Evidence<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="seasonal-influenza-outcomes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Seasonal Influenza Outcomes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Oseltamivir treatment for seasonal influenza in otherwise healthy adults consistently shortens the median time to alleviation of influenza symptoms by approximately 12 to 24 hours compared to placebo, based on randomized controlled trials and meta-analyses of individual patient data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup>62449-1/fulltext) This relative reduction translates to an absolute benefit of about 17 hours in time to first alleviation of symptoms, with greater effects observed when initiated within 12 to 24 hours of symptom onset, aligning with peak viral replication dynamics that amplify early inhibition of neuraminidase-mediated viral release.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_afabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In outpatient settings, oseltamivir also reduces the duration of absenteeism from work or normal activities by roughly 0.5 to 1 day, supporting its role in mitigating short-term productivity losses during uncomplicated seasonal episodes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> However, absolute benefits remain modest, with no significant reduction in the risk of lower respiratory tract complications such as pneumonia (risk difference near 0%) or influenza transmission to household contacts in healthy adults, as evidenced by aggregated trial data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_afqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Recent analyses of seasonal influenza outpatients confirm limited impact on hospitalization rates, with a 2023 meta-analysis finding no association between oseltamivir use and reduced admissions, prompting reevaluation of routine prescriptions given the drug&#x27;s cost and potential overestimation of benefits in low-risk populations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> While some 2024-2025 observational data indicate lower readmission risks in treated cohorts, these findings are confounded by selection biases and do not alter the primary trial evidence favoring targeted use in early symptomatic phases over broad application.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup>01307-2/fulltext)</span>
<h3 id="pandemic-and-high-risk-scenarios" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pandemic and High-Risk Scenarios<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
During the 2009 H1N1 influenza pandemic, observational studies associated early oseltamivir treatment with reduced ICU admissions and mortality in high-risk hospitalized patients, particularly when initiated within 48 hours of symptom onset.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ahabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup> For example, a multinational analysis of over 29,000 patients found neuraminidase inhibitors, mainly oseltamivir, linked to a 19% lower mortality risk compared to no treatment, with stronger effects in severe cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ehabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup> WHO surveillance data from the period similarly indicated potential reductions in disease progression for treated severe cases, though these findings relied on cohort comparisons prone to time-dependent biases where healthier patients received earlier therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ihabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mhabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Causal attribution in these scenarios remains contested, as adjustments for confounding factors like immortal time bias and competing risks often diminished or eliminated apparent mortality benefits in reanalyses of 2009 data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> A Lancet Respiratory Medicine review of 30 observational studies concluded limited evidence for oseltamivir reducing overall pandemic mortality, emphasizing reliance on surrogate endpoints over direct outcomes amid ethical barriers to randomized trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_chqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup> These debates highlight challenges in distinguishing drug effects from selection biases in emergency settings, where untreated comparators may reflect delayed care rather than absence of intervention.</span>
<span class="mb-4 block break-words text-[1em] leading-7">In high-risk avian influenza scenarios, such as H5N1 outbreaks, 2025 CDC guidance recommends prompt empiric oseltamivir for suspected human cases due to retained susceptibility in most clade 2.3.4.4b strains, despite isolated resistance markers like those in North American dairy cattle-linked variants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup> Canadian surveillance in early 2025 identified rare oseltamivir-resistant H5N1 mutations, prompting calls for genotypic monitoring of neuraminidase substitutions such as N294S, yet clinical trials affirm efficacy against wild-type viruses in severe infections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_giabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Global stockpiling of oseltamivir, initiated post-2005 avian flu threats, cost billions across high-income nations, including over $1 billion in U.S. reserves alone, but post-hoc assessments reveal limited causal reductions in pandemic mortality due to uneven distribution, prophylaxis overuse, and efficacy gaps in community settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> For the 2009 H1N1 event, despite massive deployments, modeling-driven projections overestimated population-level impacts, with empirical data showing benefits confined to hospitalized subgroups amid confounding from concurrent supportive care advances.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> Such investments underscore tensions between precautionary modeling and real-world causal evidence, where observational benefits in high-risk cohorts did not translate to broad mortality declines.</span>
<h3 id="meta-analyses-and-controversies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Meta-Analyses and Controversies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">A 2014 Cochrane systematic review, incorporating previously unpublished Roche-sponsored trials obtained through regulatory access, substantially revised prior efficacy estimates for oseltamivir in treating influenza. The analysis of 53 trials (including 20 previously unreported) found that oseltamivir shortened the duration of symptoms by about 17 hours in adults but provided no evidence of reducing hospitalizations, complications like pneumonia, or transmission risks when full datasets were included; earlier meta-analyses relying on published summaries alone had overstated these benefits due to selective reporting.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> Roche&#x27;s withholding of complete clinical study reports for over a decade, despite regulatory obligations, fueled controversy over industry transparency and potential bias in trial design favoring positive outcomes, as independent assessments revealed higher risks of bias in manufacturer-funded studies compared to non-industry ones.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ajqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A 2025 network meta-analysis of 73 randomized trials on antivirals for nonsevere influenza further questioned oseltamivir&#x27;s relative superiority, estimating it reduced symptom duration by only 0.75 days versus no treatmentâ€”less than baloxavir&#x27;s 1-day reductionâ€”while showing minimal impact on hospitalization in high-risk outpatients (risk difference -0.4%, 95% CI -1.0% to 0.4%).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup> Critics, including infectious disease experts, argued the findings overemphasize randomized controlled trial limitations like underpowering for rare events and ignore real-world observational data suggesting benefits in severe cases, potentially downplaying oseltamivir&#x27;s role amid pharmaceutical influences in endpoint selection across trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> This debate underscores causal challenges in extrapolating trial results to broader populations, where confounding factors such as timing of administration and strain variability complicate interpretations.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Economic evaluations reinforce targeted rather than universal application, with models indicating oseltamivir&#x27;s cost per quality-adjusted life year gained exceeds $50,000 in otherwise healthy adults, rendering it inefficient given modest symptom relief and generic pricing around $100 per course; benefits accrue primarily in vulnerable groups like the elderly or comorbid patients where hospitalization risks justify use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> These analyses counter optimistic narratives from early promotional data, prioritizing empirical scrutiny over unsubstantiated claims of broad prophylactic value.</span>
<h2 id="safety-and-adverse-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Safety and Adverse Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="common-side-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Common Side Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The most common adverse events associated with oseltamivir treatment are nausea and vomiting, primarily gastrointestinal in nature and typically mild to moderate in severity. In phase III clinical trials for influenza treatment in adults, nausea without vomiting occurred in approximately 10% of oseltamivir recipients compared to 6% on placebo, while vomiting affected about 9% versus 3%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup> These events were often self-limiting, occurring early in treatment, and could be mitigated by administering the drug with food, with limited discontinuations due to gastrointestinal effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In pediatric populations aged 1-12 years from phase III trials, vomiting was more frequent, reported in 14% of treated children versus 8.5% on placebo, though still generally transient and resolving without intervention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup> Discontinuation rates attributable to vomiting were approximately 1% in these studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Headache and fatigue were commonly reported across treatment and placebo groups in pooled trial data, with incidences either similar or not exceeding those in controls, suggesting no attributable excess risk from oseltamivir beyond gastrointestinal upset.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup> Overall tolerability remains high for the standard 5-day course, with adverse event-related discontinuations below 1-2% in adults and children.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup> Post-marketing surveillance aligns with trial findings, confirming these mild events as the predominant profile without evidence of increased frequency over time.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup></span>
<h3 id="serious-risks-and-warnings" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Serious Risks and Warnings<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Oseltamivir is contraindicated in patients with known serious hypersensitivity to the drug or any of its components, as severe allergic reactions, including anaphylaxis, have been reported.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Pharmacovigilance data indicate that hypersensitivity reactions occur rarely, with case reports documenting anaphylaxis in isolated instances, often linked to cross-reactivity with excipients or underlying allergies such as to star anise.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_coabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup> Disproportionality analyses from adverse event reporting systems show no strong signals for anaphylaxis specifically with oseltamivir compared to other antivirals, suggesting an incidence below 0.1% in clinical use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_goabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In patients with renal impairment, oseltamivir requires dose adjustment due to its primary renal clearance via the active metabolite oseltamivir carboxylate, with accumulation possible in creatinine clearance below 30 mL/min, potentially leading to toxicity in overdose or end-stage disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup> Case reports and post-marketing surveillance have identified rare instances of acute kidney injury associated with oseltamivir, particularly in those with pre-existing renal compromise or following overdose, though causality is not firmly established and may involve confounding factors like dehydration from influenza.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_coqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup> For end-stage renal disease patients on dialysis, dosing is limited to 30 mg after every other dialysis session to mitigate risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_goqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Drug interactions with oseltamivir are generally minimal, but co-administration with probenecid inhibits renal tubular secretion of the carboxylate metabolite, reducing clearance by approximately 50% and doubling systemic exposure, necessitating caution and potential dose reduction to avoid enhanced toxicity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup> This interaction has been confirmed in pharmacokinetic studies without evidence of increased adverse events at standard doses, but monitoring is advised in patients with renal issues or overdose risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cpabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup></span>
<h3 id="neuropsychiatric-concerns" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Neuropsychiatric Concerns<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Concerns about neuropsychiatric events, such as delirium, hallucinations, and abnormal behavior, emerged prominently following post-marketing surveillance in Japan during the early 2000s, where reports linked oseltamivir to pediatric cases amid influenza outbreaks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup> These observations prompted the FDA to add a warning to the oseltamivir label in 2007, advising monitoring for neuropsychiatric symptoms in patients, particularly children, without establishing causality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup> Japanese data, however, were confounded by influenza-related factors like high fever and delirium, which independently correlate with behavioral disturbances, and subsequent analyses found no dose-response relationship indicative of drug causation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Empirical evidence from cohort studies and meta-analyses has increasingly challenged these warnings, demonstrating that influenza infection itself elevates the risk of serious neuropsychiatric events, while oseltamivir treatment does not increaseâ€”and may reduceâ€”this risk. A large 2025 cohort study of over 100,000 pediatric influenza cases found that untreated influenza episodes were associated with higher rates of neuropsychiatric events compared to non-influenza periods, whereas oseltamivir-treated episodes showed approximately a 50% reduction in such events relative to untreated ones.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup> This pattern held across comparisons, attributing events to viral effects rather than the drug, with similar protective associations in prior observational pediatric studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Meta-analyses reinforce this, finding no association between oseltamivir and increased neuropsychiatric risks, and in some cases, evidence of mitigation, particularly when controlling for influenza severity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup> For instance, a September 2025 analysis of randomized and observational data concluded oseltamivir offers potential protective effects against behavioral adverse events, absent a causal signal from the drug.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup> These findings, prioritizing cohort comparisons over anecdotal reports, support causal attribution to influenza&#x27;s direct neurological impactsâ€”such as cytokine-mediated inflammation or rare viral neuroinvasionâ€”over oseltamivir, prompting calls for label revisions to avoid delaying treatment in high-risk scenarios.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_grabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_krabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup></span>
<h2 id="resistance" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Resistance<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="mechanisms-of-resistance" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Mechanisms of Resistance<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Resistance to oseltamivir occurs primarily through point mutations in the neuraminidase (NA) gene of influenza A and B viruses, which encode the viral sialidase enzyme targeted by the drug&#x27;s active metabolite, oseltamivir carboxylate. These mutations alter the NA active site, sterically hindering inhibitor binding or disrupting key interactions, thereby elevating the 50% inhibitory concentration (IC<sub>50</sub>) required for enzyme inhibition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_asqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The predominant mutation conferring high-level resistance in N1 subtype NA (common in human influenza A/H1N1 and A/H5N1) is histidine-to-tyrosine substitution at position 275 (H275Y, N2 numbering; H274Y in some notations), which introduces a bulkier tyrosine side chain that clashes with the hydrophobic pentyl ether group of oseltamivir carboxylate, reducing binding affinity by over 1,000-fold as measured in fluorescence-based NA inhibition assays on clinical isolates and recombinant mutants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup> In N2 subtypes and influenza B, the asparagine-to-serine change at position 294 (N294S) yields moderate resistance (10- to 100-fold IC<sub>50</sub> shift), primarily by weakening hydrogen bonding in the enzyme-inhibitor complex, as demonstrated through crystallographic studies of mutant NA structures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_etabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gtabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup> Other less frequent NA mutations, such as E119V or I223R, contribute variably but are confirmed via site-directed mutagenesis and enzymatic kinetics showing diminished substrate cleavage rates alongside resistance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ktabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mtabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">These resistance mutations typically impose a biological fitness cost, manifesting as reduced NA enzymatic activity, lower viral plaque formation, and diminished replication kinetics in cell culture and animal models, attributable to impaired sialic acid cleavage efficiency essential for viral release.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[90]</sup> In vitro serial passage experiments under oseltamivir selection pressure reveal that H275Y alone lowers peak viral titers by 10- to 100-fold in MDCK cells compared to wild-type, but co-emergence of compensatory mutationsâ€”such as R222Q or D344N in NA, or balancing changes in hemagglutinin (HA) to restore HA-NA functional balanceâ€”restores replication competence and transmissibility without fully reverting susceptibility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_atqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[91]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ctqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup> Structural analyses confirm these second-site changes stabilize the mutant NA tetramer or optimize receptor binding dynamics, enabling viable quasispecies propagation as observed in passaged isolates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gtqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup></span>
<h3 id="prevalence-across-influenza-strains" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Prevalence Across Influenza Strains<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Global surveillance through the World Health Organization&#x27;s Global Influenza Surveillance and Response System (GISRS) has documented low overall prevalence of oseltamivir resistance in circulating human influenza strains, with empirical data emphasizing subtype-specific variations rather than predictive models. Resistance rates remain below 2% across most seasonal subtypes in recent seasons, though sporadic clusters highlight transmission potential in untreated cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In influenza A(H1N1)pdm09, resistance prevalence has hovered between 0.5% and 1.8% in North American and global samples from 2014 to 2019, with a noted uptick to approximately 2.4% in the 2024-2025 season driven by the I223V + S247N neuraminidase mutations. These variants, first detected widely from May 2023 to February 2024 across five continents, confer reduced oseltamivir inhibition without fitness costs, marking a shift from the post-2009 pandemic surge where H275Y resistance exceeded 99% in some regions before declining through natural selection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[93]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[94]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[95]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For influenza A(H3N2) and B lineages, resistance remains rare at less than 1% globally, with GISRS data from 2018-2019 showing under 0.5% of isolates exhibiting reduced susceptibility, attributed to infrequent selection pressure and stable neuraminidase genetics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In avian strains like H5N1, resistance clusters are exceptional but documented in clade 2.3.4.4b isolates from Canadian poultry in 2024-2025, featuring mutations such as H275Y that reduce oseltamivir efficacy; these align with preclinical observations of diminished susceptibility in milk-associated bovine transmissions. Historical precedents include treatment failures in Vietnam in 2005, where H274Y variants emerged in fatal H5N1 cases despite standard oseltamivir dosing, underscoring early risks in non-seasonal subtypes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_70abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup></span>
<h3 id="clinical-implications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Clinical Implications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In cases of confirmed or suspected oseltamivir resistance, clinical guidelines recommend switching to alternative neuraminidase inhibitors such as zanamivir, provided susceptibility is verified through phenotypic or genotypic testing, as oseltamivir failure has been documented in resistant strains like seasonal H1N1pdm09 during treatment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_71abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[99]</sup> Updated 2025 recommendations from the Infectious Diseases Society of America (IDSA) and Centers for Disease Control and Prevention (CDC) stress initiating rapid molecular diagnostics within 48 hours of symptom onset to guide antiviral selection, particularly in hospitalized patients or outbreaks where resistance prevalence exceeds 2%, thereby minimizing empirical monotherapy risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Population-level viral dynamics underscore the hazards of widespread oseltamivir monotherapy or mass post-exposure prophylaxis, as selective pressure from suboptimal dosing or incomplete adherence can amplify transmission of resistant mutants, with modeling indicating up to 5-fold higher resistance emergence in prophylaxis scenarios compared to targeted treatment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup> Empirical data from global surveillance show resistance rates remain low at 1-3% for most circulating strains, correlating with rare clinical failures outside immunocompromised cohorts, yet causal chains in pandemicsâ€”evident in 2009 H1N1 oseltamivir-resistant clustersâ€”reveal potential for rapid fitness-compensated spread if baseline prevalence surges.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Susceptibility testing, via neuraminidase inhibition assays or sequencing for markers like H275Y in neuraminidase, is advocated for treatment non-responders or prophylaxis failures to inform regimen adjustments, as 2025 WHO protocols prioritize it in high-risk settings to avert broader dissemination without evidence of routine clinical collapse in seasonal contexts.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_72abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup> While no large-scale empirical failures have materialized, the intrinsic evolvability of influenza necessitates vigilance against complacency, as monotherapy-driven selection could precipitate untreatable outbreaks in vulnerable populations during surges.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup></span>
<h2 id="history-and-development" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History and Development<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="discovery-and-early-research" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Discovery and Early Research<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Oseltamivir, originally coded as GS4104 by Gilead Sciences, emerged from a targeted medicinal chemistry program in the early 1990s aimed at creating small-molecule inhibitors of influenza neuraminidase, an enzyme essential for viral release from host cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[108]</sup> Researchers at Gilead employed structure-based design, leveraging X-ray crystallographic data of neuraminidase to model transition-state mimics that could bind the enzyme&#x27;s active site with high affinity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[108]</sup> This approach yielded GS4071 as the potent active carboxylate inhibitor (Ki &lt;1 nM against influenza A and B strains), but its zwitterionic nature limited oral absorption to less than 5% in preclinical models.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">To overcome this bioavailability challenge, Gilead synthesized GS4104 as an ethyl ester prodrug of GS4071, facilitating passive diffusion across gastrointestinal membranes before rapid hydrolysis by carboxylesterases in the liver and intestines to release the active metabolite.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup> Preclinical pharmacokinetic studies in rodents and ferrets confirmed this activation pathway, with oral dosing of GS4104 achieving systemic exposure of GS4071 equivalent to 35% bioavailability and peak plasma concentrations sufficient for antiviral efficacy (Cmax â‰ˆ0.47 Î¼g/mL in mice).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup> In vitro enzymatic assays verified esterase-dependent conversion, with human hepatic carboxylesterase 1 identified as the primary activator, ensuring efficient prodrug metabolism without accumulation of the parent compound.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Early validation included in vitro assays demonstrating GS4071&#x27;s inhibition of neuraminidase activity across multiple influenza subtypes, reducing plaque formation in cell culture by over 90% at low micromolar concentrations of the prodrug.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[108]</sup> Animal model studies in the mid-1990s, particularly in ferretsâ€”a mammalian surrogate for human influenza pathogenesisâ€”showed that oral GS4104 dosing (e.g., 10 mg/kg) significantly lowered nasal viral titers, shortened fever duration, and mitigated weight loss compared to untreated controls infected with H1N1 or H3N2 strains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[110]</sup> These findings established causal antiviral effects grounded in neuraminidase blockade, with no evidence of host toxicity at therapeutic doses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[108]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 1996, Gilead licensed GS4104 to Hoffmann-La Roche for further clinical advancement, retaining royalties while Roche handled large-scale manufacturing and global trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[111]</sup> Phase I/II human trials, initiated in the late 1990s, involved experimentally infected volunteers and confirmed dose-dependent viral clearance (e.g., 1-2 log10 reduction in nasal shedding within 24-48 hours at 100-200 mg twice daily) alongside good tolerability, paving the way for efficacy demonstration without reliance on surrogate endpoints alone.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[112]</sup></span>
<h3 id="regulatory-approval-and-key-trials" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Regulatory Approval and Key Trials<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The U.S. Food and Drug Administration (FDA) approved oseltamivir phosphate, marketed as Tamiflu, on October 27, 1999, for the treatment of uncomplicated acute illness due to influenza A or B virus in adults capable of self-care, based on two pivotal phase III randomized, double-blind, placebo-controlled trials demonstrating reductions in symptom duration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[113]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_76abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[114]</sup> In these trials, involving over 1,000 naturally infected adults treated within 40 hours of symptom onset, the primary empirical endpoint was the median time to alleviation of seven influenza symptoms (e.g., headache, myalgia, cough), which was shortened by approximately 30 hours (1.3 days) with 75 mg twice-daily oseltamivir compared to placebo (71% vs. 62% alleviation by day 3 in one trial).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[114]</sup> Viral titers and shedding were secondary virological endpoints, but approval emphasized clinical symptom relief over surrogates like viral load reduction. The FDA expanded approval to an oral suspension for children aged 1 year and older on December 14, 2000, following supportive pediatric data extrapolated from adult trials and smaller studies showing similar proportional symptom reductions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup> Prophylactic use for post-exposure prevention was approved in November 2001, supported by trials in household contacts and immunocompromised adults where oseltamivir reduced influenza incidence by 89-92%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The European Medicines Agency (EMA) granted centralized marketing authorization for oseltamivir on June 20, 2002, for similar indications in adults and children over 1 year, relying on the same core dataset of treatment and prophylaxis trials with consistent empirical outcomes on symptom duration and incidence prevention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[117]</sup> These approvals prioritized clinical endpoints like time-to-alleviation over virological markers, as trials measured patient-reported symptom relief via daily diaries rather than hospitalization or mortality, which were rare events in uncomplicated outpatient populations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[114]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">During the 2009 H1N1 influenza pandemic, the FDA issued Emergency Use Authorizations (EUAs) on April 27, 2009, expanding oseltamivir dosing to infants under 1 year and intravenous formulations for hospitalized patients, based on observational data and in vitro susceptibility rather than new large-scale RCTs specific to the strain.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[118]</sup> Governments worldwide stockpiled billions of treatment courses, including over 1 billion doses secured by the U.S. alone, leveraging existing trial evidence of symptom reduction despite gaps in strain-specific efficacy trials at pandemic onset.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[118]</sup> Subsequent amendments through 2010 refined pediatric dosing under EUA, maintaining focus on empirical symptom management in resource-limited settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[119]</sup></span>
<h3 id="data-transparency-and-policy-debates" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Data Transparency and Policy Debates<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The Cochrane Collaboration&#x27;s 2014 systematic review of oseltamivir, based on full clinical study reports from 25 trials involving over 9,000 participants, concluded that the drug shortened symptom duration by about 17 hours in adults but provided no evidence of reducing influenza complications such as pneumonia or transmission to household contacts, contradicting earlier manufacturer claims of broader benefits derived from partial summary data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup> These findings emerged after sustained pressure from independent researchers and outlets like the BMJ, which from 2009 onward campaigned for Roche to release complete trial data from the 1990s onward, as regulatory summaries had overstated efficacy while omitting key safety and transmission details.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_98abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[121]</sup> Roche finally agreed in April 2013 to provide access to all 77 oseltamivir trials&#x27; raw data following this advocacy, revealing discrepancies that highlighted risks of relying on industry-provided summaries prone to selective reporting.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[122]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Government stockpiling policies amplified these transparency issues, with nations expending billions on oseltamivir reserves justified by modeling projections of pandemic utility rather than robust causal evidence from full datasets. The United States allocated over $1.3 billion between 2005 and the early 2010s for approximately 65 million treatment courses, while the United Kingdom spent Â£473 million by 2014 on stockpiles for pandemic preparedness, decisions influenced by pre-2014 partial data suggesting stronger preventive effects against spread.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> Post-Cochrane analysis indicated these investments lacked empirical support for averting severe outcomes or transmission at scale, prompting critiques of fiscal inefficiency in public health spending driven by alliances between pharmaceutical firms and agencies favoring precautionary models over verified trial outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_98qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[123]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In September 2025, the UK government removed seasonal prescribing restrictions on oseltamivir, permitting year-round use by physicians and pharmacists to enhance outbreak response flexibility, a shift from prior flu-season-only protocols amid ongoing debates over the drug&#x27;s marginal benefits outside confirmed epidemics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[124]</sup> This relaxation occurs against evidence from comprehensive reviews questioning routine off-season deployment, as oseltamivir&#x27;s prophylaxis efficacy remains limited to reducing symptomatic cases by 55% in exposed groups without proven impact on hospitalizations or broader containment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_99abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup> Such policy adjustments underscore persistent tensions between adaptive procurement strategies and the causal uncertainties exposed by delayed data access, with independent analyses emphasizing the need for skepticism toward unverified modeling in antiviral allocation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup></span>
<h2 id="non-human-applications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Non-Human Applications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="veterinary-use" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Veterinary Use<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Oseltamivir has been investigated for off-label use in poultry to mitigate outbreaks of highly pathogenic avian influenza (HPAI), particularly H5N1 strains, with studies demonstrating reduced viral replication and transmission in infected chickens.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[125]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[126]</sup> Systemic administration limits severe morbidity, mortality, and chicken-to-chicken spread of HPAI virus, though efficacy varies by strain pathogenicity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_baqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[126]</sup> However, resistance has emerged in poultry isolates, such as clade 2.3.4.4b H5N1 viruses exhibiting a 161.4-fold increase in oseltamivir IC50 values due to neuraminidase mutations like H275Y.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_faqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[127]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In swine models of influenza A virus infection, oseltamivir treatment significantly delays and reduces nasal virus shedding compared to untreated controls, supporting its experimental application against porcine strains.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup> Pharmacokinetic studies in juvenile pigs confirm bioavailability of oseltamivir formulations, with plasma concentrations measurable up to 48 hours post-administration, though metabolic differences from humans may influence dosing requirements.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[129]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Regulatory restrictions limit veterinary applications to preserve oseltamivir&#x27;s efficacy for human use, particularly amid concerns over resistance transfer from animals. In 2006, the U.S. Food and Drug Administration prohibited extralabel use of neuraminidase inhibitors, including oseltamivir, in chickens, turkeys, and ducks due to risks of antiviral resistance development in influenza viruses circulating in poultry flocks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[130]</sup> This measure addresses potential residue accumulation and cross-species transmission of resistant strains, prioritizing human pandemic preparedness over routine animal prophylaxis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[131]</sup></span>
<h2 id="current-research-and-alternatives" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Current Research and Alternatives<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="emerging-studies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Emerging Studies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">A multicenter cohort study published in <em>JAMA Network Open</em> on June 10, 2025, examined oseltamivir treatment versus supportive care in adults hospitalized with seasonal influenza, finding lower in-hospital mortality (3.5% versus 4.9%; adjusted risk difference -1.8%), shorter hospital stays, and reduced 30-day readmission rates among those treated within 2 days of admission.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> However, as an observational study using overlap weighting to adjust for confounders, it remains susceptible to unmeasured biases, such as healthier patients receiving antivirals preferentially, and lacks randomization to definitively establish causality.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ddabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Similar observational data from 2025 reinforce reduced mortality risks even with delayed oseltamivir initiation beyond 48 hours in older adults, though randomized controlled trials (RCTs) specifically targeting mortality endpoints in hospitalized patients continue to show evidence gaps.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Recent analyses have addressed longstanding concerns about neuropsychiatric adverse events in pediatric use, with a <em>JAMA Neurology</em> study from August 4, 2025, analyzing over 3 million children and finding no increased risk of such events with oseltamivir treatment for influenza; instead, influenza itself elevated risks, and treatment was linked to decreased severe neuropsychiatric outcomes in subgroup analyses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup> A September 2025 meta-analysis of observational data further confirmed no association with neuropsychiatric or behavioral events, potentially challenging prior label warnings based on early post-marketing reports, though prospective RCTs in children for these rare endpoints remain limited.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ddqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Preclinical research from St. Jude Children&#x27;s Research Hospital, reported March 17, 2025, tested oseltamivir in mouse models of severe H5N1 avian influenza infection simulating exposure via contaminated bovine milk, revealing limited efficacy in reducing mortality or viral loads during high-dose, systemic disease phases compared to milder models.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[132]</sup> These findings highlight potential vulnerabilities in oseltamivir&#x27;s neuraminidase inhibition against highly pathogenic strains in severe contexts, underscoring the need for strain-specific RCTs or combination therapies, as susceptibility testing showed retained activity but suboptimal clinical translation in advanced infection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[132]</sup> Overall, while 2023-2025 data bolster supportive roles for oseltamivir in reducing hospitalization burdens, persistent reliance on non-randomized designs perpetuates uncertainties in mortality benefits and resistance scenarios.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_deabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_feabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup></span>
<h3 id="comparative-antivirals" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Comparative Antivirals<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Oseltamivir, an oral neuraminidase inhibitor, is compared to other influenza antivirals including zanamivir (inhaled), peramivir (intravenous), and baloxavir marboxil (single-dose oral endonuclease inhibitor). Head-to-head trials and meta-analyses indicate broadly similar clinical efficacy in reducing symptom duration and hospitalization risk across these agents, with differences primarily in administration route, adherence, and resistance emergence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[133]</sup>01307-2/fulltext) For uncomplicated outpatient influenza, oseltamivir&#x27;s five-day oral regimen achieves noninferiority to zanamivir&#x27;s inhaled delivery in preventing hospitalization or death, though inhalation poses adherence challenges due to device use and patient technique, leading to higher non-persistence rates than oral therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[134]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[135]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Zanamivir avoids gastrointestinal side effects common with oseltamivir, such as nausea (affecting up to 10% of users), but its respiratory delivery limits utility in patients with airway compromise and correlates with lower compliance in real-world settings compared to oral oseltamivir.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[136]</sup> Peramivir, reserved for hospitalized patients unable to tolerate oral intake, demonstrates comparable reductions in hospital length of stay to oseltamivir (low-certainty evidence from network meta-analysis), with a single intravenous dose option providing convenience in acute settings but requiring vascular access.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[137]</sup>01307-2/fulltext)</span>
<span class="mb-4 block break-words text-[1em] leading-7">Baloxavir offers a single-dose advantage, shortening fever duration by approximately 13 hours more than oseltamivir in some meta-analyses and reducing hospitalization incidence (0.15% vs. 0.37%; risk ratio 2.48), particularly for influenza B.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[138]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[139]</sup> However, its monotherapy raises concerns for rapid resistance emergence, as modeling shows potential acceleration of variants under widespread use, contrasting oseltamivir&#x27;s established but subtype-specific resistance patterns (e.g., H1N1).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[140]</sup> Baloxavir&#x27;s higher cost and limited long-term safety data relative to oseltamivir&#x27;s extensive profile contribute to its selective use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_fgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[141]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Guidelines from the CDC prioritize oseltamivir for outpatients due to its oral bioavailability, pediatric dosing flexibility, and accumulation of empirical evidence, despite no consistent superiority in direct comparisons; alternatives like zanamivir or peramivir are recommended for oseltamivir resistance or contraindications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[142]</sup> This preference reflects practical considerations over marginal efficacy gains, with combination or sequential therapy explored for severe cases but lacking routine endorsement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tamiflu-oseltamivir-phosphate-information" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tamiflu-oseltamivir-phosphate-information" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tamiflu-oseltamivir-phosphate-information</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK539909/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK539909/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK539909/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2835511/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2835511/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2835511/</a></span></div></li><li id="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2805976" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2805976" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2805976</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835158" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835158" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835158</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4375804/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4375804/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4375804/</a></span></div></li><li id="https://www.cdc.gov/flu/treatment/antiviral-drugs.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/flu/treatment/antiviral-drugs.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/flu/treatment/antiviral-drugs.html</a></span></div></li><li id="https://academic.oup.com/jac/article/74/2/453/5173728" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/jac/article/74/2/453/5173728" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/jac/article/74/2/453/5173728</a></span></div></li><li id="https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html</a></span></div></li><li id="https://go.drugbank.com/drugs/DB00198" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://go.drugbank.com/drugs/DB00198" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://go.drugbank.com/drugs/DB00198</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMra050740" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMra050740" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMra050740</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2932999/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2932999/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2932999/</a></span></div></li><li id="https://journals.asm.org/doi/10.1128/aac.00333-08" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.asm.org/doi/10.1128/aac.00333-08" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.asm.org/doi/10.1128/aac.00333-08</a></span></div></li><li id="https://www.nature.com/articles/nature06956" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/nature06956" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/nature06956</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2565879/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2565879/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2565879/</a></span></div></li><li id="https://reference.medscape.com/drug/tamiflu-oseltamivir-342618" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://reference.medscape.com/drug/tamiflu-oseltamivir-342618" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://reference.medscape.com/drug/tamiflu-oseltamivir-342618</a></span></div></li><li id="https://www.ema.europa.eu/en/documents/product-information/tamiflu-epar-product-information_en.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/documents/product-information/tamiflu-epar-product-information_en.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ema.europa.eu/en/documents/product-information/tamiflu-epar-product-information_en.pdf</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/19995812/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/19995812/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/19995812/</a></span></div></li><li id="https://www.who.int/publications/i/item/9789240097759" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.who.int/publications/i/item/9789240097759" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.who.int/publications/i/item/9789240097759</a></span></div></li><li id="https://www.drugs.com/availability/generic-tamiflu.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/availability/generic-tamiflu.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/availability/generic-tamiflu.html</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021087s071%2C021246s054lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021087s071%2C021246s054lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021087s071%2C021246s054lbl.pdf</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021087s070lbl%2C%2520021246s053lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021087s070lbl%2C%2520021246s053lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021087s070lbl%2C%2520021246s053lbl.pdf</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/11176912/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/11176912/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/11176912/</a></span></div></li><li id="https://www.ajpmonline.org/article/S0749-3797%2809%2900527-3/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajpmonline.org/article/S0749-3797%2809%2900527-3/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajpmonline.org/article/S0749-3797%2809%2900527-3/fulltext</a></span></div></li><li id="https://www.drugs.com/dosage/tamiflu.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/dosage/tamiflu.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/dosage/tamiflu.html</a></span></div></li><li id="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2901357-6/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2901357-6/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2901357-6/fulltext</a></span></div></li><li id="https://stacks.cdc.gov/view/cdc/17978/cdc_17978_DS1.pdf?" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://stacks.cdc.gov/view/cdc/17978/cdc_17978_DS1.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://stacks.cdc.gov/view/cdc/17978/cdc_17978_DS1.pdf</a>?</span></div></li><li id="https://journals.sagepub.com/doi/pdf/10.3851/IMP2192" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.sagepub.com/doi/pdf/10.3851/IMP2192" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.sagepub.com/doi/pdf/10.3851/IMP2192</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6492654/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6492654/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6492654/</a></span></div></li><li id="https://www.cdc.gov/flu/hcp/antivirals/treatment_obstetric.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/flu/hcp/antivirals/treatment_obstetric.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/flu/hcp/antivirals/treatment_obstetric.html</a></span></div></li><li id="https://academic.oup.com/ofid/article/8/6/ofab138/6179259" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ofid/article/8/6/ofab138/6179259" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ofid/article/8/6/ofab138/6179259</a></span></div></li><li id="https://www.researchgate.net/publication/45268377_Safety_of_Oseltamivir_in_Pregnancy_A_Review_of_Preclinical_and_Clinical_Data" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.researchgate.net/publication/45268377_Safety_of_Oseltamivir_in_Pregnancy_A_Review_of_Preclinical_and_Clinical_Data" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.researchgate.net/publication/45268377_Safety_of_Oseltamivir_in_Pregnancy_A_Review_of_Preclinical_and_Clinical_Data</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/39968306/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/39968306/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/39968306/</a></span></div></li><li id="https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2829156" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2829156" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2829156</a></span></div></li><li id="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/full</a></span></div></li><li id="https://thennt.com/nnt/neuraminidase-inhibitors-treatment-influenza/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://thennt.com/nnt/neuraminidase-inhibitors-treatment-influenza/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://thennt.com/nnt/neuraminidase-inhibitors-treatment-influenza/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2840043/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2840043/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2840043/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2491667/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2491667/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2491667/</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMopv0910738" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMopv0910738" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMopv0910738</a></span></div></li><li id="https://jamanetwork.com/journals/jamapediatrics/fullarticle/2796162" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamapediatrics/fullarticle/2796162" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamapediatrics/fullarticle/2796162</a></span></div></li><li id="https://www.cidrap.umn.edu/h1n1-2009-pandemic-influenza/large-study-shows-tamiflu-cut-h1n1-pandemic-deaths" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cidrap.umn.edu/h1n1-2009-pandemic-influenza/large-study-shows-tamiflu-cut-h1n1-pandemic-deaths" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cidrap.umn.edu/h1n1-2009-pandemic-influenza/large-study-shows-tamiflu-cut-h1n1-pandemic-deaths</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMra1000449" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMra1000449" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMra1000449</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0895435616302669" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0895435616302669" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0895435616302669</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK363115/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK363115/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK363115/</a></span></div></li><li id="https://www.cebm.net/announcement/no-effect-oseltamivir-mortality-patients-2009ah1n1-influenza/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cebm.net/announcement/no-effect-oseltamivir-mortality-patients-2009ah1n1-influenza/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cebm.net/announcement/no-effect-oseltamivir-mortality-patients-2009ah1n1-influenza/</a></span></div></li><li id="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2814%2970041-4/abstract" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2814%2970041-4/abstract" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2814%2970041-4/abstract</a></span></div></li><li id="https://www.cdc.gov/bird-flu/hcp/clinicians-evaluating-patients/interim-guidance-treatment-humans.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/bird-flu/hcp/clinicians-evaluating-patients/interim-guidance-treatment-humans.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/bird-flu/hcp/clinicians-evaluating-patients/interim-guidance-treatment-humans.html</a></span></div></li><li id="https://www.cidrap.umn.edu/avian-influenza-bird-flu/exceptionally-rare-mutation-h5n1-virus-canada-tied-antiviral-drug" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cidrap.umn.edu/avian-influenza-bird-flu/exceptionally-rare-mutation-h5n1-virus-canada-tied-antiviral-drug" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cidrap.umn.edu/avian-influenza-bird-flu/exceptionally-rare-mutation-h5n1-virus-canada-tied-antiviral-drug</a></span></div></li><li id="https://wwwnc.cdc.gov/eid/article/31/4/24-1820_article" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://wwwnc.cdc.gov/eid/article/31/4/24-1820_article" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://wwwnc.cdc.gov/eid/article/31/4/24-1820_article</a></span></div></li><li id="https://cdn.who.int/media/docs/default-source/influenza/laboratory---network/quality-assurance/human-nai-marker-table_for-publication_final_20240918.pdf?sfvrsn=c6d153ec_3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://cdn.who.int/media/docs/default-source/influenza/laboratory---network/quality-assurance/human-nai-marker-table_for-publication_final_20240918.pdf?sfvrsn=c6d153ec_3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://cdn.who.int/media/docs/default-source/influenza/laboratory---network/quality-assurance/human-nai-marker-table_for-publication_final_20240918.pdf?sfvrsn=c6d153ec_3</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4880079/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4880079/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4880079/</a></span></div></li><li id="https://wwwnc.cdc.gov/eid/article/22/6/15-1037_article" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://wwwnc.cdc.gov/eid/article/22/6/15-1037_article" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://wwwnc.cdc.gov/eid/article/22/6/15-1037_article</a></span></div></li><li id="https://www.bmj.com/content/341/bmj.c4779" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bmj.com/content/341/bmj.c4779" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bmj.com/content/341/bmj.c4779</a></span></div></li><li id="https://www.bmj.com/content/348/bmj.g2545" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bmj.com/content/348/bmj.g2545" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bmj.com/content/348/bmj.g2545</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4179405/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4179405/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4179405/</a></span></div></li><li id="https://www.theguardian.com/business/2014/apr/10/tamiflu-saga-drug-trials-big-pharma" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.theguardian.com/business/2014/apr/10/tamiflu-saga-drug-trials-big-pharma" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.theguardian.com/business/2014/apr/10/tamiflu-saga-drug-trials-big-pharma</a></span></div></li><li id="https://www.cidrap.umn.edu/influenza-general/experts-say-recent-network-meta-analysis-wont-change-flu-antiviral-practices" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cidrap.umn.edu/influenza-general/experts-say-recent-network-meta-analysis-wont-change-flu-antiviral-practices" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cidrap.umn.edu/influenza-general/experts-say-recent-network-meta-analysis-wont-change-flu-antiviral-practices</a></span></div></li><li id="https://www.valueinhealthjournal.com/article/S1098-3015%2810%2960141-6/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.valueinhealthjournal.com/article/S1098-3015%2810%2960141-6/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.valueinhealthjournal.com/article/S1098-3015%2810%2960141-6/fulltext</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10290610/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10290610/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10290610/</a></span></div></li><li id="https://www.cdc.gov/flu/hcp/antivirals/antiviral-adverse-events.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/flu/hcp/antivirals/antiviral-adverse-events.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/flu/hcp/antivirals/antiviral-adverse-events.html</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21087_Tamiflu_medr_P1.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21087_Tamiflu_medr_P1.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21087_Tamiflu_medr_P1.pdf</a></span></div></li><li id="https://www.drugs.com/sfx/oseltamivir-side-effects.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/sfx/oseltamivir-side-effects.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/sfx/oseltamivir-side-effects.html</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/12493796/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/12493796/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/12493796/</a></span></div></li><li id="https://www.researchgate.net/publication/5663579_Anaphylaxis_after_Oseltamivir_TamifluR_therapy_in_a_patient_with_sensitization_to_star_anise_and_celery-carrot-mugwort-spice_syndrome" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.researchgate.net/publication/5663579_Anaphylaxis_after_Oseltamivir_TamifluR_therapy_in_a_patient_with_sensitization_to_star_anise_and_celery-carrot-mugwort-spice_syndrome" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.researchgate.net/publication/5663579_Anaphylaxis_after_Oseltamivir_TamifluR_therapy_in_a_patient_with_sensitization_to_star_anise_and_celery-carrot-mugwort-spice_syndrome</a></span></div></li><li id="https://www.ovid.com/journals/hpha/pdf/10.1310/hpj4608-591~possible-oseltamivir-induced-angioedema-in-a-patient-with" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ovid.com/journals/hpha/pdf/10.1310/hpj4608-591~possible-oseltamivir-induced-angioedema-in-a-patient-with" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ovid.com/journals/hpha/pdf/10.1310/hpj4608-591~possible-oseltamivir-induced-angioedema-in-a-patient-with</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11266138/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11266138/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11266138/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/32947554/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/32947554/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/32947554/</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021087s062lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021087s062lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021087s062lbl.pdf</a></span></div></li><li id="https://www.droracle.ai/articles/1882/can-tamiflu-affect-kidneys-causing-aki-after-4-days-" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.droracle.ai/articles/1882/can-tamiflu-affect-kidneys-causing-aki-after-4-days-" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.droracle.ai/articles/1882/can-tamiflu-affect-kidneys-causing-aki-after-4-days-</a></span></div></li><li id="https://archive.cdc.gov/www_cdc_gov/flu/professionals/antivirals/antiviral-drug-interactions.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://archive.cdc.gov/www_cdc_gov/flu/professionals/antivirals/antiviral-drug-interactions.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://archive.cdc.gov/www_cdc_gov/flu/professionals/antivirals/antiviral-drug-interactions.htm</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMc052951" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMc052951" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMc052951</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2533494/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2533494/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2533494/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5201449/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5201449/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5201449/</a></span></div></li><li id="https://www.medpagetoday.com/neurology/generalneurology/116827" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.medpagetoday.com/neurology/generalneurology/116827" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.medpagetoday.com/neurology/generalneurology/116827</a></span></div></li><li id="https://www.rescp.org/journal/download_pdf.php?doi=10.59931/rcp.25.0007" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.rescp.org/journal/download_pdf.php?doi=10.59931/rcp.25.0007" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.rescp.org/journal/download_pdf.php?doi=10.59931/rcp.25.0007</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/28818475/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/28818475/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/28818475/</a></span></div></li><li id="https://jamanetwork.com/journals/jamaneurology/fullarticle/2837165" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamaneurology/fullarticle/2837165" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamaneurology/fullarticle/2837165</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/40758339/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/40758339/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/40758339/</a></span></div></li><li id="https://www.jmcp.org/doi/10.18553/jmcp.2025.31.10.1051" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jmcp.org/doi/10.18553/jmcp.2025.31.10.1051" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jmcp.org/doi/10.18553/jmcp.2025.31.10.1051</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12467762/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12467762/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12467762/</a></span></div></li><li id="https://www.news-medical.net/news/20250804/Flu-virus-triggers-neuropsychiatric-symptoms-not-the-medication.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.news-medical.net/news/20250804/Flu-virus-triggers-neuropsychiatric-symptoms-not-the-medication.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.news-medical.net/news/20250804/Flu-virus-triggers-neuropsychiatric-symptoms-not-the-medication.aspx</a></span></div></li><li id="https://www.cidrap.umn.edu/influenza-general/influenza-not-tamiflu-may-raise-risk-neuropsychiatric-events-kids" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cidrap.umn.edu/influenza-general/influenza-not-tamiflu-may-raise-risk-neuropsychiatric-events-kids" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cidrap.umn.edu/influenza-general/influenza-not-tamiflu-may-raise-risk-neuropsychiatric-events-kids</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11600549/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11600549/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11600549/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6499333/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6499333/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6499333/</a></span></div></li><li id="https://www.news-medical.net/health/Tamiflu-Oseltamivir-Resistance.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.news-medical.net/health/Tamiflu-Oseltamivir-Resistance.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.news-medical.net/health/Tamiflu-Oseltamivir-Resistance.aspx</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1111/irv.12047" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1111/irv.12047" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1111/irv.12047</a></span></div></li><li id="https://cpb.iphy.ac.cn/article/2018/1919/cpb_27_1_018704.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://cpb.iphy.ac.cn/article/2018/1919/cpb_27_1_018704.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://cpb.iphy.ac.cn/article/2018/1919/cpb_27_1_018704.html</a></span></div></li><li id="https://www.tandfonline.com/doi/full/10.2147/IDR.S36601" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tandfonline.com/doi/full/10.2147/IDR.S36601" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tandfonline.com/doi/full/10.2147/IDR.S36601</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4886345/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4886345/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4886345/</a></span></div></li><li id="https://journals.asm.org/doi/10.1128/aac.02628-13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.asm.org/doi/10.1128/aac.02628-13" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.asm.org/doi/10.1128/aac.02628-13</a></span></div></li><li id="https://www.nature.com/articles/ncomms6029" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/ncomms6029" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/ncomms6029</a></span></div></li><li id="https://journals.asm.org/doi/10.1128/jvi.00918-22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.asm.org/doi/10.1128/jvi.00918-22" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.asm.org/doi/10.1128/jvi.00918-22</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12270646/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12270646/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12270646/</a></span></div></li><li id="https://www.health-providers.ir/article_220683_899673f3e0c831ce455365d9df071d69.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.health-providers.ir/article_220683_899673f3e0c831ce455365d9df071d69.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.health-providers.ir/article_220683_899673f3e0c831ce455365d9df071d69.pdf</a></span></div></li><li id="https://wwwnc.cdc.gov/eid/article/30/7/24-0480_article" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://wwwnc.cdc.gov/eid/article/30/7/24-0480_article" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://wwwnc.cdc.gov/eid/article/30/7/24-0480_article</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12253934/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12253934/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12253934/</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa054512" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa054512" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa054512</a></span></div></li><li id="https://www.cdc.gov/flu/treatment/antiviralresistance.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cdc.gov/flu/treatment/antiviralresistance.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cdc.gov/flu/treatment/antiviralresistance.html</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12537536/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12537536/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12537536/</a></span></div></li><li id="https://journals.lww.com/idi/fulltext/2025/07000/critical_updates_in_the_2024_influenza_clinical.2.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/idi/fulltext/2025/07000/critical_updates_in_the_2024_influenza_clinical.2.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/idi/fulltext/2025/07000/critical_updates_in_the_2024_influenza_clinical.2.aspx</a></span></div></li><li id="https://wwwnc.cdc.gov/eid/article/15/10/08-1129_article" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://wwwnc.cdc.gov/eid/article/15/10/08-1129_article" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://wwwnc.cdc.gov/eid/article/15/10/08-1129_article</a></span></div></li><li id="https://www.mdpi.com/1999-4915/7/9/2850" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mdpi.com/1999-4915/7/9/2850" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mdpi.com/1999-4915/7/9/2850</a></span></div></li><li id="https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.865001/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.865001/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.865001/full</a></span></div></li><li id="https://www.who.int/teams/global-influenza-programme/laboratory-network/quality-assurance/antiviral-susceptibility-influenza" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.who.int/teams/global-influenza-programme/laboratory-network/quality-assurance/antiviral-susceptibility-influenza" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.who.int/teams/global-influenza-programme/laboratory-network/quality-assurance/antiviral-susceptibility-influenza</a></span></div></li><li id="https://academic.oup.com/jid/article/232/Supplement_3/S273/8287901" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/jid/article/232/Supplement_3/S273/8287901" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/jid/article/232/Supplement_3/S273/8287901</a></span></div></li><li id="https://journals.asm.org/doi/10.1128/cmr.00224-20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.asm.org/doi/10.1128/cmr.00224-20" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.asm.org/doi/10.1128/cmr.00224-20</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMp058291" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMp058291" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMp058291</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/10702632/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/10702632/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/10702632/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/9517946/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/9517946/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/9517946/</a></span></div></li><li id="https://journals.sagepub.com/doi/10.1177/13596535211067598" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.sagepub.com/doi/10.1177/13596535211067598" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.sagepub.com/doi/10.1177/13596535211067598</a></span></div></li><li id="https://www.gilead.com/news/news-details/2005/gilead-and-roche-end-tamiflur-dispute-expanded-collaboration-includes-gilead-role-in-oversight-of-manufacturing-and-commercialization" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gilead.com/news/news-details/2005/gilead-and-roche-end-tamiflur-dispute-expanded-collaboration-includes-gilead-role-in-oversight-of-manufacturing-and-commercialization" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gilead.com/news/news-details/2005/gilead-and-roche-end-tamiflur-dispute-expanded-collaboration-includes-gilead-role-in-oversight-of-manufacturing-and-commercialization</a></span></div></li><li id="https://jamanetwork.com/journals/jama/fullarticle/191957" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jama/fullarticle/191957" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jama/fullarticle/191957</a></span></div></li><li id="https://www.gilead.com/news/news-details/1999/roche-receives-fda-approval-of-tamiflu-first-pill-to-treat-the-most-common-strains-of-influenza-ab" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gilead.com/news/news-details/1999/roche-receives-fda-approval-of-tamiflu-first-pill-to-treat-the-most-common-strains-of-influenza-ab" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gilead.com/news/news-details/1999/roche-receives-fda-approval-of-tamiflu-first-pill-to-treat-the-most-common-strains-of-influenza-ab</a></span></div></li><li id="https://jamanetwork.com/journals/jama/fullarticle/192425" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jama/fullarticle/192425" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jama/fullarticle/192425</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-246_Tamiflu.cfm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-246_Tamiflu.cfm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-246_Tamiflu.cfm</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021246Orig1s045_021087Orig1s062OtherR.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021246Orig1s045_021087Orig1s062OtherR.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021246Orig1s045_021087Orig1s062OtherR.pdf</a></span></div></li><li id="https://www.ema.europa.eu/en/medicines/human/EPAR/tamiflu" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/medicines/human/EPAR/tamiflu" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ema.europa.eu/en/medicines/human/EPAR/tamiflu</a></span></div></li><li id="https://www.federalregister.gov/documents/2009/08/04/E9-18568/authorizations-of-emergency-use-of-certain-antiviral-drugs-zanamivir-and-oseltamivir-phosphate" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.federalregister.gov/documents/2009/08/04/E9-18568/authorizations-of-emergency-use-of-certain-antiviral-drugs-zanamivir-and-oseltamivir-phosphate" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.federalregister.gov/documents/2009/08/04/E9-18568/authorizations-of-emergency-use-of-certain-antiviral-drugs-zanamivir-and-oseltamivir-phosphate</a></span></div></li><li id="https://www.federalregister.gov/documents/2010/04/19/2010-8603/amended-authorizations-of-emergency-use-of-certain-antiviral-drugs-zanamivir-and-oseltamivir" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.federalregister.gov/documents/2010/04/19/2010-8603/amended-authorizations-of-emergency-use-of-certain-antiviral-drugs-zanamivir-and-oseltamivir" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.federalregister.gov/documents/2010/04/19/2010-8603/amended-authorizations-of-emergency-use-of-certain-antiviral-drugs-zanamivir-and-oseltamivir</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3981975/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3981975/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3981975/</a></span></div></li><li id="https://www.bmj.com/tamiflu" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bmj.com/tamiflu" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bmj.com/tamiflu</a></span></div></li><li id="https://www.bbc.com/news/health-22029708" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bbc.com/news/health-22029708" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bbc.com/news/health-22029708</a></span></div></li><li id="https://www.bbc.com/news/health-26954482" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bbc.com/news/health-26954482" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bbc.com/news/health-26954482</a></span></div></li><li id="https://www.gov.uk/government/news/government-to-combat-flu-outbreaks-by-removing-red-tape" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.gov.uk/government/news/government-to-combat-flu-outbreaks-by-removing-red-tape" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.gov.uk/government/news/government-to-combat-flu-outbreaks-by-removing-red-tape</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11054683/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11054683/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11054683/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0531513104000214" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0531513104000214" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0531513104000214</a></span></div></li><li id="https://www.tandfonline.com/doi/full/10.1080/22221751.2025.2469643" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tandfonline.com/doi/full/10.1080/22221751.2025.2469643" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tandfonline.com/doi/full/10.1080/22221751.2025.2469643</a></span></div></li><li id="https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2022.999507/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2022.999507/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2022.999507/full</a></span></div></li><li id="https://www.tandfonline.com/doi/abs/10.1080/17576180.2024.2352256" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tandfonline.com/doi/abs/10.1080/17576180.2024.2352256" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.tandfonline.com/doi/abs/10.1080/17576180.2024.2352256</a></span></div></li><li id="https://www.federalregister.gov/documents/2006/03/22/06-2689/new-animal-drugs-adamantane-and-neuraminidase-inhibitor-anti-influenza-drugs-extralabel-animal-drug" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.federalregister.gov/documents/2006/03/22/06-2689/new-animal-drugs-adamantane-and-neuraminidase-inhibitor-anti-influenza-drugs-extralabel-animal-drug" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.federalregister.gov/documents/2006/03/22/06-2689/new-animal-drugs-adamantane-and-neuraminidase-inhibitor-anti-influenza-drugs-extralabel-animal-drug</a></span></div></li><li id="https://www.merckvetmanual.com/pharmacology/antiviral-agents/overview-of-antiviral-agents-used-in-animals" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.merckvetmanual.com/pharmacology/antiviral-agents/overview-of-antiviral-agents-used-in-animals" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.merckvetmanual.com/pharmacology/antiviral-agents/overview-of-antiviral-agents-used-in-animals</a></span></div></li><li id="https://www.stjude.org/media-resources/news-releases/2025-medicine-science-news/current-antivirals-likely-less-effective-against-severe-infection-caused-by-bird-flu-in-cows-milk.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.stjude.org/media-resources/news-releases/2025-medicine-science-news/current-antivirals-likely-less-effective-against-severe-infection-caused-by-bird-flu-in-cows-milk.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.stjude.org/media-resources/news-releases/2025-medicine-science-news/current-antivirals-likely-less-effective-against-severe-infection-caused-by-bird-flu-in-cows-milk.html</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8363918/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8363918/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8363918/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/35299245/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/35299245/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/35299245/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC5734282/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5734282/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC5734282/</a></span></div></li><li id="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782995" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782995" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782995</a></span></div></li><li id="https://www.acpjournals.org/doi/10.7326/ANNALS-24-03198-JC" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.acpjournals.org/doi/10.7326/ANNALS-24-03198-JC" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.acpjournals.org/doi/10.7326/ANNALS-24-03198-JC</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/39529764/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/39529764/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/39529764/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11347862/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11347862/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11347862/</a></span></div></li><li id="https://academic.oup.com/jid/article/232/Supplement_3/S299/8287909" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/jid/article/232/Supplement_3/S299/8287909" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/jid/article/232/Supplement_3/S299/8287909</a></span></div></li><li id="https://www.uspharmacist.com/article/comparing-oral-antiviral-agents-for-seasonal-influenza" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uspharmacist.com/article/comparing-oral-antiviral-agents-for-seasonal-influenza" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uspharmacist.com/article/comparing-oral-antiviral-agents-for-seasonal-influenza</a></span></div></li><li id="https://www.uspharmacist.com/article/antiviral-recommendations-for-the-2022-2023-influenza-season" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uspharmacist.com/article/antiviral-recommendations-for-the-2022-2023-influenza-season" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uspharmacist.com/article/antiviral-recommendations-for-the-2022-2023-influenza-season</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3" id="_R_" async=""></script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\"}]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Oseltamivir\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Oseltamivir\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Oseltamivir\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:Tf7be,"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"# Oseltamivir\n\n![Oseltamivir chemical structure](./_assets_/Oseltamivir.svg.png)  \nOseltamivir is an oral antiviral prodrug indicated for the treatment of acute uncomplicated influenza A and B infections in patients two weeks of age and older who have been symptomatic for no more than two days, as well as for post-exposure prophylaxis in individuals one year and older.[](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tamiflu-oseltamivir-phosphate-information)[](https://www.ncbi.nlm.nih.gov/books/NBK539909/) Developed by Gilead Sciences and marketed by Roche under the brand name Tamiflu, it functions as a neuraminidase inhibitor; after hydrolysis in the liver to its active carboxylate metabolite, this compound competitively binds to the active site of the viral neuraminidase enzyme, thereby inhibiting the cleavage of sialic acid residues on host cells and preventing the release of progeny virions.[](https://www.ncbi.nlm.nih.gov/books/NBK539909/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2835511/)\n\nClinical trials and meta-analyses have demonstrated that oseltamivir shortens the median duration of influenza symptoms by approximately 12 to 29 hours in adults and children, respectively, compared to placebo, though benefits on preventing complications such as lower respiratory tract infections or hospitalization appear limited in otherwise healthy outpatients.62449-1/abstract)[](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2805976) In hospitalized patients with severe influenza, however, treatment has been associated with reduced mortality and shorter hospital stays, particularly when initiated early.01307-2/fulltext)[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835158) The drug's efficacy is most pronounced against susceptible strains, but resistance can emerge, as observed in seasonal H1N1 variants during widespread use.[](https://www.ncbi.nlm.nih.gov/books/NBK539909/)\n\nOseltamivir has faced scrutiny over its modest clinical impact relative to high stockpiling costs during pandemics like H1N1 in 2009, with independent reviews revealing that manufacturer-held trial data overstated benefits on complications and transmission, leading to questions about regulatory reliance on incomplete submissions.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4375804/) Common adverse effects include nausea and vomiting in up to 10% of users, while rare but serious neuropsychiatric eventsâ€”such as delirium, hallucinations, and self-harmâ€”have been reported, disproportionately in pediatric populations, prompting warnings for behavioral monitoring.[](https://www.cdc.gov/flu/treatment/antiviral-drugs.html)[](https://academic.oup.com/jac/article/74/2/453/5173728) Despite these concerns, it remains a cornerstone of influenza management in high-risk groups due to limited alternatives.[](https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html)\n\n## Pharmacology\n\n### Mechanism of Action\n\nOseltamivir is an ethyl ester prodrug rapidly hydrolyzed by endogenous carboxylesterases, primarily in the liver, to its active metabolite oseltamivir carboxylate, which exerts the antiviral effect.[](https://www.ncbi.nlm.nih.gov/books/NBK539909/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2835511/) Oseltamivir carboxylate functions as a competitive inhibitor of the neuraminidase (NA) enzyme, a surface glycoprotein unique to influenza A and B viruses that is essential for viral replication.[](https://go.drugbank.com/drugs/DB00198)[](https://www.nejm.org/doi/full/10.1056/NEJMra050740)\n\nThe NA enzyme cleaves terminal sialic acid residues linked by Î±-2,3 or Î±-2,6 glycosidic bonds to oligosaccharides on the host cell surface and viral glycoproteins, enabling the release of progeny virions from infected cells and preventing their aggregation via multivalent sialic acid interactions.[](https://www.nejm.org/doi/full/10.1056/NEJMra050740)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2932999/) Oseltamivir carboxylate binds tightly to the enzyme's active site, mimicking the planar oxocarbonium ion transition state of sialic acid during hydrolysis, with the inhibitor's carboxylate group forming ionic interactions and its hydrophobic pentyloxy substituent occupying a conserved pocket adjacent to the sialic acid-binding region.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2932999/) This binding inhibits NA activity, trapping virions on the host cell surface and limiting cell-to-cell spread within the respiratory tract.[](https://go.drugbank.com/drugs/DB00198)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2835511/)\n\nEnzymatic inhibition assays demonstrate high potency against influenza A and B NAs, with IC\u003csub\u003e50\u003c/sub\u003e values for oseltamivir carboxylate typically in the low nanomolar range (e.g., 1.4â€“3.7 nM across susceptible strains), reflecting its structural optimization as a transition-state analog.[](https://journals.asm.org/doi/10.1128/aac.00333-08) The inhibitor exhibits specificity for viral NAs, showing negligible activity against mammalian sialidases or those from non-influenza viruses due to differences in active site architecture.[](https://go.drugbank.com/drugs/DB00198)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2932999/)\n\nX-ray crystallographic analyses of NA-oseltamivir carboxylate complexes confirm the molecular basis of inhibition, revealing hydrogen bonds between the inhibitor's functional groups and conserved arginine residues (e.g., Arg118, Arg292, Arg371) in the active site, alongside van der Waals contacts that stabilize the enzyme-inhibitor complex across influenza subtypes.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2932999/)[](https://www.nature.com/articles/nature06956) These interactions underscore the drug's design, derived from sialic acid analogs, to exploit the catalytic mechanism of NA without affecting host enzymes.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2932999/)\n\n### Pharmacokinetics\n\nOseltamivir phosphate, the prodrug form of oseltamivir, is administered orally and readily absorbed from the gastrointestinal tract, with at least 75% of the dose systemically available as the active metabolite oseltamivir carboxylate following rapid hydrolysis by hepatic esterases; less than 5% circulates as unchanged prodrug. Plasma concentrations of oseltamivir carboxylate are proportional to dose and exhibit high bioavailability unaffected by concomitant food intake, with peak levels typically attained 3 to 4 hours post-administration.[](https://www.ncbi.nlm.nih.gov/books/NBK539909/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2835511/)\n\nThe apparent elimination half-life of oseltamivir is 1 to 3 hours, whereas oseltamivir carboxylate persists longer with a half-life of 6 to 10 hours. Elimination of the active metabolite occurs almost entirely via renal excretion (\u003e90% of dose recovered in urine), involving glomerular filtration and active tubular secretion, as indicated by its renal clearance of 18.8 L/h exceeding the glomerular filtration rate of 7.5 L/h.\n\nThe volume of distribution for oseltamivir carboxylate is 23 to 26 L, with minimal plasma protein binding (~3%), reflecting limited tissue distribution. Due to its low lipophilicity and polarity, oseltamivir carboxylate demonstrates restricted penetration across the blood-brain barrier.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2565879/) In patients with renal impairment, accumulation of oseltamivir carboxylate occurs with declining creatinine clearance, requiring dosage reductions such as 30 mg twice daily for treatment in those with clearance of 30 to 60 mL/min.[](https://reference.medscape.com/drug/tamiflu-oseltamivir-342618)\n\n## Clinical Uses\n\n### Treatment Indications\n\nOseltamivir is approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute uncomplicated influenza in patients two weeks of age and older who have been symptomatic for no more than 48 hours, targeting influenza A and B viruses.[](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tamiflu-oseltamivir-phosphate-information) The European Medicines Agency (EMA) authorizes its use for treating influenza in adults and children one year of age or older presenting with typical symptoms, when influenza is circulating in the community, with extensions to full-term newborns in certain contexts.[](https://www.ema.europa.eu/en/documents/product-information/tamiflu-epar-product-information_en.pdf) These indications stem from randomized controlled trials showing oseltamivir shortens the duration of symptoms and reduces viral shedding compared to placebo.\n\nPivotal clinical trials, as synthesized in the 2009 Cochrane review by Jefferson et al., demonstrated that oseltamivir reduces the time to alleviation of influenza symptoms by approximately 1 day (29 hours) in adults with laboratory-confirmed cases when initiated within 48 hours of onset.[](https://pubmed.ncbi.nlm.nih.gov/19995812/) In children, similar trials reported a reduction of about 0.8 days in symptom duration.[](https://pubmed.ncbi.nlm.nih.gov/19995812/) Oseltamivir also decreases the duration of viral shedding by 1 to 2 days, limiting infectiousness, based on virological endpoints from these studies.[](https://pubmed.ncbi.nlm.nih.gov/19995812/)\n\nThe Centers for Disease Control and Prevention (CDC) recommends oseltamivir for treating influenza in outpatients with uncomplicated illness, emphasizing initiation as soon as possible, ideally within 48 hours, to achieve these benefits.[](https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html) For hospitalized patients or those with severe or complicated influenza, CDC guidelines endorse oseltamivir regardless of symptom duration, with evidence from observational data and trials indicating modest reductions in complications like pneumonia in high-risk groups such as the elderly or those with comorbidities.[](https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html) The World Health Organization (WHO) similarly advises oseltamivir for severe influenza cases, prioritizing empirical outcomes in resource-variable settings.[](https://www.who.int/publications/i/item/9789240097759)\n\nSince the expiration of key patents in 2016, generic oseltamivir has become widely available, lowering costs and enhancing treatment access in low- and middle-income countries where branded formulations were prohibitive.[](https://www.drugs.com/availability/generic-tamiflu.html) This shift has supported broader deployment during seasonal outbreaks without compromising the drug's established dosing regimen of 75 mg twice daily for 5 days in adults.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021087s071%2C021246s054lbl.pdf)\n\n### Prophylaxis Applications\n\nOseltamivir is approved for post-exposure prophylaxis (PEP) against influenza A and B viruses when administered within 48 hours of exposure to a confirmed case, particularly in household settings where transmission risk is elevated.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021087s070lbl%2C%2520021246s053lbl.pdf) Randomized controlled trials have demonstrated protective efficacy ranging from 70% to 89% against symptomatic influenza illness in household contacts, with one double-blind study of 457 contacts reporting an 89% reduction (95% CI, 67%-96%) in clinical influenza when oseltamivir was given as 75 mg once daily for 7 to 10 days.[](https://pubmed.ncbi.nlm.nih.gov/11176912/)[](https://www.ajpmonline.org/article/S0749-3797%2809%2900527-3/fulltext) These protocols emphasize short-term administration, typically 10 days, to target immediate transmission prevention while aligning with trial durations that confirmed efficacy without extending exposure to unnecessary selective pressure.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021087s070lbl%2C%2520021246s053lbl.pdf)\n\nFor adults and adolescents aged 13 years and older, the standard PEP regimen is 75 mg orally once daily for at least 10 days, adjustable based on renal function (e.g., reduced to 75 mg every other day for creatinine clearance 10-30 mL/min).[](https://www.drugs.com/dosage/tamiflu.html)[](https://reference.medscape.com/drug/tamiflu-oseltamivir-342618) Seasonal prophylaxis applications include use during community outbreaks or in institutional settings, such as nursing homes, where oseltamivir has shown reductions in influenza incidence when initiated early, though evidence derives primarily from targeted rather than broad implementation.[](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2901357-6/fulltext) However, large-scale community-wide prophylaxis strategies, including stockpiling for pandemic scenarios like the 2009 H1N1 outbreak, have demonstrated limited causal impact on overall transmission at the population level, as global spread persisted despite distribution of over 220 million courses across multiple countries.[](https://stacks.cdc.gov/view/cdc/17978/cdc_17978_DS1.pdf?)\n\nIn immunocompromised individuals, such as transplant recipients, oseltamivir prophylaxis reduces culture- or PCR-confirmed influenza incidence (e.g., from 5.4% to 1.6% in one randomized trial), but breakthrough infections occur at higher rates than in immunocompetent populations, necessitating individualized assessment and often combination with vaccination or monitoring for resistance.[](https://journals.sagepub.com/doi/pdf/10.3851/IMP2192) Guidelines recommend its use in high-risk exposure scenarios for this group, though efficacy data highlight incomplete protection, with some studies reporting persistent viral shedding despite prophylaxis.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6492654/)\n\n### Use in Special Populations\n\nOseltamivir is approved by the U.S. Food and Drug Administration for the treatment of acute uncomplicated influenza in pediatric patients aged 1 year and older, with dosing determined by body weight: for children weighing less than 15 kg, the recommended dose is 30 mg orally twice daily for 5 days; for 15 to 22.9 kg, 45 mg twice daily; for 23 to 40 kg, 60 mg twice daily; and for those over 40 kg, 75 mg twice daily. Clinical trials in children aged 1 to 12 years demonstrated a reduction in the median time to symptom alleviation by approximately 21 to 29 hours compared to placebo when initiated within 48 hours of symptom onset.[](https://www.ncbi.nlm.nih.gov/books/NBK539909/) However, vomiting occurs more frequently in this population, affecting about 16% of treated children aged 1 to 12 years versus 8% in placebo groups, though this adverse effect is generally self-limited and does not typically necessitate discontinuation.[](https://www.ncbi.nlm.nih.gov/books/NBK539909/) Use in infants under 1 year remains off-label due to insufficient safety and efficacy data from controlled trials, although the American Academy of Pediatrics suggests weight-based dosing (e.g., 3 mg/kg twice daily for those under 3 months in severe cases) based on observational evidence of potential benefit in hospitalized neonates.[](https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html)\n\nIn pregnant women, oseltamivir carries an FDA Pregnancy Category C designation, indicating that animal reproduction studies have not shown adverse effects but adequate human studies are lacking, necessitating a risk-benefit assessment.[](https://www.cdc.gov/flu/hcp/antivirals/treatment_obstetric.html) The Centers for Disease Control and Prevention recommend prompt initiation for suspected or confirmed influenza, particularly in cases of severe illness or hospitalization, supported by observational studies from registries like the U.S. Pregnancy Risk Assessment Monitoring System showing reduced maternal hospitalization rates (odds ratio 0.44) and lower risks of preterm birth or fetal loss when treated early.[](https://academic.oup.com/ofid/article/8/6/ofab138/6179259) Limited randomized controlled trials exist due to ethical constraints, but post-marketing surveillance data through 2024, including over 1,000 exposures, report no consistent signals of teratogenicity or fetal harm.[](https://www.researchgate.net/publication/45268377_Safety_of_Oseltamivir_in_Pregnancy_A_Review_of_Preclinical_and_Clinical_Data) The standard adult dose of 75 mg twice daily for 5 days is used without adjustment, and breastfeeding is considered compatible given minimal drug transfer into breast milk.[](https://www.cdc.gov/flu/hcp/antivirals/treatment_obstetric.html)\n\nFor elderly patients and those with high-risk comorbidities (e.g., chronic pulmonary or cardiovascular disease), oseltamivir is recommended within 48 hours of symptom onset to mitigate progression, with real-world cohort studies indicating reduced odds of hospitalization; for instance, a 2025 analysis in *JAMA Network Open* of over 10,000 hospitalized influenza cases found early treatment associated with a 25% lower risk of intensive care admission in older adults aged 65 and above. Subgroup analyses from propensity-matched observational data further show shortened hospital stays (by 1-2 days) and decreased 30-day readmission rates in this demographic.[](https://pubmed.ncbi.nlm.nih.gov/39968306/) Nonetheless, meta-analyses of randomized trials reveal no significant mortality benefit in all elderly subgroups, with hazard ratios around 0.90-1.00 for death, particularly absent in non-hospitalized or low-risk elderly where evidence gaps persist due to underrepresentation in pivotal studies.[](https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2829156) Dosing remains 75 mg twice daily unless renal impairment requires adjustment (e.g., 75 mg once daily for creatinine clearance 30-60 mL/min).[](https://www.ncbi.nlm.nih.gov/books/NBK539909/)\n\n## Efficacy and Evidence\n\n### Seasonal Influenza Outcomes\n\nOseltamivir treatment for seasonal influenza in otherwise healthy adults consistently shortens the median time to alleviation of influenza symptoms by approximately 12 to 24 hours compared to placebo, based on randomized controlled trials and meta-analyses of individual patient data.[](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/full)62449-1/fulltext) This relative reduction translates to an absolute benefit of about 17 hours in time to first alleviation of symptoms, with greater effects observed when initiated within 12 to 24 hours of symptom onset, aligning with peak viral replication dynamics that amplify early inhibition of neuraminidase-mediated viral release.[](https://thennt.com/nnt/neuraminidase-inhibitors-treatment-influenza/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2840043/)\n\nIn outpatient settings, oseltamivir also reduces the duration of absenteeism from work or normal activities by roughly 0.5 to 1 day, supporting its role in mitigating short-term productivity losses during uncomplicated seasonal episodes.[](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/full) However, absolute benefits remain modest, with no significant reduction in the risk of lower respiratory tract complications such as pneumonia (risk difference near 0%) or influenza transmission to household contacts in healthy adults, as evidenced by aggregated trial data.[](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/full)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2491667/)\n\nRecent analyses of seasonal influenza outpatients confirm limited impact on hospitalization rates, with a 2023 meta-analysis finding no association between oseltamivir use and reduced admissions, prompting reevaluation of routine prescriptions given the drug's cost and potential overestimation of benefits in low-risk populations.[](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2805976) While some 2024-2025 observational data indicate lower readmission risks in treated cohorts, these findings are confounded by selection biases and do not alter the primary trial evidence favoring targeted use in early symptomatic phases over broad application.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835158)01307-2/fulltext)\n\n### Pandemic and High-Risk Scenarios\n\n![H1N1 virus](./_assets_/H1N1_navbox.jpg)\nDuring the 2009 H1N1 influenza pandemic, observational studies associated early oseltamivir treatment with reduced ICU admissions and mortality in high-risk hospitalized patients, particularly when initiated within 48 hours of symptom onset.[](https://www.nejm.org/doi/full/10.1056/NEJMopv0910738) [](https://jamanetwork.com/journals/jamapediatrics/fullarticle/2796162) For example, a multinational analysis of over 29,000 patients found neuraminidase inhibitors, mainly oseltamivir, linked to a 19% lower mortality risk compared to no treatment, with stronger effects in severe cases.[](https://www.cidrap.umn.edu/h1n1-2009-pandemic-influenza/large-study-shows-tamiflu-cut-h1n1-pandemic-deaths) WHO surveillance data from the period similarly indicated potential reductions in disease progression for treated severe cases, though these findings relied on cohort comparisons prone to time-dependent biases where healthier patients received earlier therapy.[](https://www.nejm.org/doi/full/10.1056/NEJMra1000449) [](https://www.sciencedirect.com/science/article/abs/pii/S0895435616302669)\n\nCausal attribution in these scenarios remains contested, as adjustments for confounding factors like immortal time bias and competing risks often diminished or eliminated apparent mortality benefits in reanalyses of 2009 data.[](https://www.ncbi.nlm.nih.gov/books/NBK363115/) [](https://www.cebm.net/announcement/no-effect-oseltamivir-mortality-patients-2009ah1n1-influenza/) A Lancet Respiratory Medicine review of 30 observational studies concluded limited evidence for oseltamivir reducing overall pandemic mortality, emphasizing reliance on surrogate endpoints over direct outcomes amid ethical barriers to randomized trials.[](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2814%2970041-4/abstract) These debates highlight challenges in distinguishing drug effects from selection biases in emergency settings, where untreated comparators may reflect delayed care rather than absence of intervention.\n\nIn high-risk avian influenza scenarios, such as H5N1 outbreaks, 2025 CDC guidance recommends prompt empiric oseltamivir for suspected human cases due to retained susceptibility in most clade 2.3.4.4b strains, despite isolated resistance markers like those in North American dairy cattle-linked variants.[](https://www.cdc.gov/bird-flu/hcp/clinicians-evaluating-patients/interim-guidance-treatment-humans.html) [](https://www.cidrap.umn.edu/avian-influenza-bird-flu/exceptionally-rare-mutation-h5n1-virus-canada-tied-antiviral-drug) Canadian surveillance in early 2025 identified rare oseltamivir-resistant H5N1 mutations, prompting calls for genotypic monitoring of neuraminidase substitutions such as N294S, yet clinical trials affirm efficacy against wild-type viruses in severe infections.[](https://wwwnc.cdc.gov/eid/article/31/4/24-1820_article) [](https://cdn.who.int/media/docs/default-source/influenza/laboratory---network/quality-assurance/human-nai-marker-table_for-publication_final_20240918.pdf?sfvrsn=c6d153ec_3)\n\nGlobal stockpiling of oseltamivir, initiated post-2005 avian flu threats, cost billions across high-income nations, including over $1 billion in U.S. reserves alone, but post-hoc assessments reveal limited causal reductions in pandemic mortality due to uneven distribution, prophylaxis overuse, and efficacy gaps in community settings.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4880079/) [](https://wwwnc.cdc.gov/eid/article/22/6/15-1037_article) For the 2009 H1N1 event, despite massive deployments, modeling-driven projections overestimated population-level impacts, with empirical data showing benefits confined to hospitalized subgroups amid confounding from concurrent supportive care advances.[](https://www.bmj.com/content/341/bmj.c4779) Such investments underscore tensions between precautionary modeling and real-world causal evidence, where observational benefits in high-risk cohorts did not translate to broad mortality declines.\n\n### Meta-Analyses and Controversies\n\nA 2014 Cochrane systematic review, incorporating previously unpublished Roche-sponsored trials obtained through regulatory access, substantially revised prior efficacy estimates for oseltamivir in treating influenza. The analysis of 53 trials (including 20 previously unreported) found that oseltamivir shortened the duration of symptoms by about 17 hours in adults but provided no evidence of reducing hospitalizations, complications like pneumonia, or transmission risks when full datasets were included; earlier meta-analyses relying on published summaries alone had overstated these benefits due to selective reporting.[](https://www.bmj.com/content/348/bmj.g2545)[](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/full) Roche's withholding of complete clinical study reports for over a decade, despite regulatory obligations, fueled controversy over industry transparency and potential bias in trial design favoring positive outcomes, as independent assessments revealed higher risks of bias in manufacturer-funded studies compared to non-industry ones.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4179405/)[](https://www.theguardian.com/business/2014/apr/10/tamiflu-saga-drug-trials-big-pharma)\n\nA 2025 network meta-analysis of 73 randomized trials on antivirals for nonsevere influenza further questioned oseltamivir's relative superiority, estimating it reduced symptom duration by only 0.75 days versus no treatmentâ€”less than baloxavir's 1-day reductionâ€”while showing minimal impact on hospitalization in high-risk outpatients (risk difference -0.4%, 95% CI -1.0% to 0.4%).[](https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2829156) Critics, including infectious disease experts, argued the findings overemphasize randomized controlled trial limitations like underpowering for rare events and ignore real-world observational data suggesting benefits in severe cases, potentially downplaying oseltamivir's role amid pharmaceutical influences in endpoint selection across trials.[](https://www.cidrap.umn.edu/influenza-general/experts-say-recent-network-meta-analysis-wont-change-flu-antiviral-practices) This debate underscores causal challenges in extrapolating trial results to broader populations, where confounding factors such as timing of administration and strain variability complicate interpretations.\n\nEconomic evaluations reinforce targeted rather than universal application, with models indicating oseltamivir's cost per quality-adjusted life year gained exceeds $50,000 in otherwise healthy adults, rendering it inefficient given modest symptom relief and generic pricing around $100 per course; benefits accrue primarily in vulnerable groups like the elderly or comorbid patients where hospitalization risks justify use.[](https://www.valueinhealthjournal.com/article/S1098-3015%2810%2960141-6/fulltext)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10290610/) These analyses counter optimistic narratives from early promotional data, prioritizing empirical scrutiny over unsubstantiated claims of broad prophylactic value.\n\n## Safety and Adverse Effects\n\n### Common Side Effects\n\nThe most common adverse events associated with oseltamivir treatment are nausea and vomiting, primarily gastrointestinal in nature and typically mild to moderate in severity. In phase III clinical trials for influenza treatment in adults, nausea without vomiting occurred in approximately 10% of oseltamivir recipients compared to 6% on placebo, while vomiting affected about 9% versus 3%.[](https://www.cdc.gov/flu/hcp/antivirals/antiviral-adverse-events.html) These events were often self-limiting, occurring early in treatment, and could be mitigated by administering the drug with food, with limited discontinuations due to gastrointestinal effects.[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21087_Tamiflu_medr_P1.pdf)\n\nIn pediatric populations aged 1-12 years from phase III trials, vomiting was more frequent, reported in 14% of treated children versus 8.5% on placebo, though still generally transient and resolving without intervention.[](https://www.cdc.gov/flu/hcp/antivirals/antiviral-adverse-events.html) Discontinuation rates attributable to vomiting were approximately 1% in these studies.[](https://www.cdc.gov/flu/hcp/antivirals/antiviral-adverse-events.html)\n\nHeadache and fatigue were commonly reported across treatment and placebo groups in pooled trial data, with incidences either similar or not exceeding those in controls, suggesting no attributable excess risk from oseltamivir beyond gastrointestinal upset.[](https://www.drugs.com/sfx/oseltamivir-side-effects.html) Overall tolerability remains high for the standard 5-day course, with adverse event-related discontinuations below 1-2% in adults and children.[](https://pubmed.ncbi.nlm.nih.gov/12493796/) Post-marketing surveillance aligns with trial findings, confirming these mild events as the predominant profile without evidence of increased frequency over time.[](https://www.cdc.gov/flu/hcp/antivirals/antiviral-adverse-events.html)\n\n### Serious Risks and Warnings\n\nOseltamivir is contraindicated in patients with known serious hypersensitivity to the drug or any of its components, as severe allergic reactions, including anaphylaxis, have been reported.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021087s071%2C021246s054lbl.pdf) Pharmacovigilance data indicate that hypersensitivity reactions occur rarely, with case reports documenting anaphylaxis in isolated instances, often linked to cross-reactivity with excipients or underlying allergies such as to star anise.[](https://www.researchgate.net/publication/5663579_Anaphylaxis_after_Oseltamivir_TamifluR_therapy_in_a_patient_with_sensitization_to_star_anise_and_celery-carrot-mugwort-spice_syndrome) [](https://www.ovid.com/journals/hpha/pdf/10.1310/hpj4608-591~possible-oseltamivir-induced-angioedema-in-a-patient-with) Disproportionality analyses from adverse event reporting systems show no strong signals for anaphylaxis specifically with oseltamivir compared to other antivirals, suggesting an incidence below 0.1% in clinical use.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11266138/)\n\nIn patients with renal impairment, oseltamivir requires dose adjustment due to its primary renal clearance via the active metabolite oseltamivir carboxylate, with accumulation possible in creatinine clearance below 30 mL/min, potentially leading to toxicity in overdose or end-stage disease.[](https://pubmed.ncbi.nlm.nih.gov/32947554/) [](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021087s062lbl.pdf) Case reports and post-marketing surveillance have identified rare instances of acute kidney injury associated with oseltamivir, particularly in those with pre-existing renal compromise or following overdose, though causality is not firmly established and may involve confounding factors like dehydration from influenza.[](https://www.droracle.ai/articles/1882/can-tamiflu-affect-kidneys-causing-aki-after-4-days-) For end-stage renal disease patients on dialysis, dosing is limited to 30 mg after every other dialysis session to mitigate risks.[](https://reference.medscape.com/drug/tamiflu-oseltamivir-342618)\n\nDrug interactions with oseltamivir are generally minimal, but co-administration with probenecid inhibits renal tubular secretion of the carboxylate metabolite, reducing clearance by approximately 50% and doubling systemic exposure, necessitating caution and potential dose reduction to avoid enhanced toxicity.[](https://archive.cdc.gov/www_cdc_gov/flu/professionals/antivirals/antiviral-drug-interactions.htm) [](https://www.nejm.org/doi/full/10.1056/NEJMc052951) This interaction has been confirmed in pharmacokinetic studies without evidence of increased adverse events at standard doses, but monitoring is advised in patients with renal issues or overdose risk.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2533494/)\n\n### Neuropsychiatric Concerns\n\nConcerns about neuropsychiatric events, such as delirium, hallucinations, and abnormal behavior, emerged prominently following post-marketing surveillance in Japan during the early 2000s, where reports linked oseltamivir to pediatric cases amid influenza outbreaks.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5201449/) These observations prompted the FDA to add a warning to the oseltamivir label in 2007, advising monitoring for neuropsychiatric symptoms in patients, particularly children, without establishing causality.[](https://www.medpagetoday.com/neurology/generalneurology/116827) Japanese data, however, were confounded by influenza-related factors like high fever and delirium, which independently correlate with behavioral disturbances, and subsequent analyses found no dose-response relationship indicative of drug causation.[](https://www.rescp.org/journal/download_pdf.php?doi=10.59931/rcp.25.0007) [](https://pubmed.ncbi.nlm.nih.gov/28818475/)\n\nEmpirical evidence from cohort studies and meta-analyses has increasingly challenged these warnings, demonstrating that influenza infection itself elevates the risk of serious neuropsychiatric events, while oseltamivir treatment does not increaseâ€”and may reduceâ€”this risk. A large 2025 cohort study of over 100,000 pediatric influenza cases found that untreated influenza episodes were associated with higher rates of neuropsychiatric events compared to non-influenza periods, whereas oseltamivir-treated episodes showed approximately a 50% reduction in such events relative to untreated ones.[](https://jamanetwork.com/journals/jamaneurology/fullarticle/2837165) [](https://pubmed.ncbi.nlm.nih.gov/40758339/) This pattern held across comparisons, attributing events to viral effects rather than the drug, with similar protective associations in prior observational pediatric studies.[](https://jamanetwork.com/journals/jamaneurology/fullarticle/2837165)\n\nMeta-analyses reinforce this, finding no association between oseltamivir and increased neuropsychiatric risks, and in some cases, evidence of mitigation, particularly when controlling for influenza severity.[](https://www.jmcp.org/doi/10.18553/jmcp.2025.31.10.1051) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467762/) For instance, a September 2025 analysis of randomized and observational data concluded oseltamivir offers potential protective effects against behavioral adverse events, absent a causal signal from the drug.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467762/) These findings, prioritizing cohort comparisons over anecdotal reports, support causal attribution to influenza's direct neurological impactsâ€”such as cytokine-mediated inflammation or rare viral neuroinvasionâ€”over oseltamivir, prompting calls for label revisions to avoid delaying treatment in high-risk scenarios.[](https://www.news-medical.net/news/20250804/Flu-virus-triggers-neuropsychiatric-symptoms-not-the-medication.aspx) [](https://www.cidrap.umn.edu/influenza-general/influenza-not-tamiflu-may-raise-risk-neuropsychiatric-events-kids)\n\n## Resistance\n\n### Mechanisms of Resistance\n\nResistance to oseltamivir occurs primarily through point mutations in the neuraminidase (NA) gene of influenza A and B viruses, which encode the viral sialidase enzyme targeted by the drug's active metabolite, oseltamivir carboxylate. These mutations alter the NA active site, sterically hindering inhibitor binding or disrupting key interactions, thereby elevating the 50% inhibitory concentration (IC\u003csub\u003e50\u003c/sub\u003e) required for enzyme inhibition.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11600549/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6499333/)\n\nThe predominant mutation conferring high-level resistance in N1 subtype NA (common in human influenza A/H1N1 and A/H5N1) is histidine-to-tyrosine substitution at position 275 (H275Y, N2 numbering; H274Y in some notations), which introduces a bulkier tyrosine side chain that clashes with the hydrophobic pentyl ether group of oseltamivir carboxylate, reducing binding affinity by over 1,000-fold as measured in fluorescence-based NA inhibition assays on clinical isolates and recombinant mutants.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11600549/)[](https://www.news-medical.net/health/Tamiflu-Oseltamivir-Resistance.aspx) In N2 subtypes and influenza B, the asparagine-to-serine change at position 294 (N294S) yields moderate resistance (10- to 100-fold IC\u003csub\u003e50\u003c/sub\u003e shift), primarily by weakening hydrogen bonding in the enzyme-inhibitor complex, as demonstrated through crystallographic studies of mutant NA structures.[](https://onlinelibrary.wiley.com/doi/10.1111/irv.12047)[](https://cpb.iphy.ac.cn/article/2018/1919/cpb_27_1_018704.html) Other less frequent NA mutations, such as E119V or I223R, contribute variably but are confirmed via site-directed mutagenesis and enzymatic kinetics showing diminished substrate cleavage rates alongside resistance.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6499333/)[](https://www.tandfonline.com/doi/full/10.2147/IDR.S36601)\n\nThese resistance mutations typically impose a biological fitness cost, manifesting as reduced NA enzymatic activity, lower viral plaque formation, and diminished replication kinetics in cell culture and animal models, attributable to impaired sialic acid cleavage efficiency essential for viral release.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4886345/)[](https://journals.asm.org/doi/10.1128/aac.02628-13) In vitro serial passage experiments under oseltamivir selection pressure reveal that H275Y alone lowers peak viral titers by 10- to 100-fold in MDCK cells compared to wild-type, but co-emergence of compensatory mutationsâ€”such as R222Q or D344N in NA, or balancing changes in hemagglutinin (HA) to restore HA-NA functional balanceâ€”restores replication competence and transmissibility without fully reverting susceptibility.[](https://www.nature.com/articles/ncomms6029)[](https://journals.asm.org/doi/10.1128/jvi.00918-22) Structural analyses confirm these second-site changes stabilize the mutant NA tetramer or optimize receptor binding dynamics, enabling viable quasispecies propagation as observed in passaged isolates.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4886345/)\n\n### Prevalence Across Influenza Strains\n\nGlobal surveillance through the World Health Organization's Global Influenza Surveillance and Response System (GISRS) has documented low overall prevalence of oseltamivir resistance in circulating human influenza strains, with empirical data emphasizing subtype-specific variations rather than predictive models. Resistance rates remain below 2% across most seasonal subtypes in recent seasons, though sporadic clusters highlight transmission potential in untreated cases.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11600549/)\n\nIn influenza A(H1N1)pdm09, resistance prevalence has hovered between 0.5% and 1.8% in North American and global samples from 2014 to 2019, with a noted uptick to approximately 2.4% in the 2024-2025 season driven by the I223V + S247N neuraminidase mutations. These variants, first detected widely from May 2023 to February 2024 across five continents, confer reduced oseltamivir inhibition without fitness costs, marking a shift from the post-2009 pandemic surge where H275Y resistance exceeded 99% in some regions before declining through natural selection.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12270646/)[](https://www.health-providers.ir/article_220683_899673f3e0c831ce455365d9df071d69.pdf)[](https://wwwnc.cdc.gov/eid/article/30/7/24-0480_article)\n\nFor influenza A(H3N2) and B lineages, resistance remains rare at less than 1% globally, with GISRS data from 2018-2019 showing under 0.5% of isolates exhibiting reduced susceptibility, attributed to infrequent selection pressure and stable neuraminidase genetics.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11600549/)\n\nIn avian strains like H5N1, resistance clusters are exceptional but documented in clade 2.3.4.4b isolates from Canadian poultry in 2024-2025, featuring mutations such as H275Y that reduce oseltamivir efficacy; these align with preclinical observations of diminished susceptibility in milk-associated bovine transmissions. Historical precedents include treatment failures in Vietnam in 2005, where H274Y variants emerged in fatal H5N1 cases despite standard oseltamivir dosing, underscoring early risks in non-seasonal subtypes.[](https://www.cidrap.umn.edu/avian-influenza-bird-flu/exceptionally-rare-mutation-h5n1-virus-canada-tied-antiviral-drug)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12253934/)[](https://www.nejm.org/doi/full/10.1056/NEJMoa054512)\n\n### Clinical Implications\n\nIn cases of confirmed or suspected oseltamivir resistance, clinical guidelines recommend switching to alternative neuraminidase inhibitors such as zanamivir, provided susceptibility is verified through phenotypic or genotypic testing, as oseltamivir failure has been documented in resistant strains like seasonal H1N1pdm09 during treatment.[](https://www.cdc.gov/flu/treatment/antiviralresistance.html)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12537536/) Updated 2025 recommendations from the Infectious Diseases Society of America (IDSA) and Centers for Disease Control and Prevention (CDC) stress initiating rapid molecular diagnostics within 48 hours of symptom onset to guide antiviral selection, particularly in hospitalized patients or outbreaks where resistance prevalence exceeds 2%, thereby minimizing empirical monotherapy risks.[](https://journals.lww.com/idi/fulltext/2025/07000/critical_updates_in_the_2024_influenza_clinical.2.aspx)[](https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html)\n\nPopulation-level viral dynamics underscore the hazards of widespread oseltamivir monotherapy or mass post-exposure prophylaxis, as selective pressure from suboptimal dosing or incomplete adherence can amplify transmission of resistant mutants, with modeling indicating up to 5-fold higher resistance emergence in prophylaxis scenarios compared to targeted treatment.[](https://wwwnc.cdc.gov/eid/article/15/10/08-1129_article) Empirical data from global surveillance show resistance rates remain low at 1-3% for most circulating strains, correlating with rare clinical failures outside immunocompromised cohorts, yet causal chains in pandemicsâ€”evident in 2009 H1N1 oseltamivir-resistant clustersâ€”reveal potential for rapid fitness-compensated spread if baseline prevalence surges.[](https://www.mdpi.com/1999-4915/7/9/2850)[](https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.865001/full)\n\nSusceptibility testing, via neuraminidase inhibition assays or sequencing for markers like H275Y in neuraminidase, is advocated for treatment non-responders or prophylaxis failures to inform regimen adjustments, as 2025 WHO protocols prioritize it in high-risk settings to avert broader dissemination without evidence of routine clinical collapse in seasonal contexts.[](https://www.who.int/teams/global-influenza-programme/laboratory-network/quality-assurance/antiviral-susceptibility-influenza)[](https://academic.oup.com/jid/article/232/Supplement_3/S273/8287901) While no large-scale empirical failures have materialized, the intrinsic evolvability of influenza necessitates vigilance against complacency, as monotherapy-driven selection could precipitate untreatable outbreaks in vulnerable populations during surges.[](https://journals.asm.org/doi/10.1128/cmr.00224-20)[](https://www.nejm.org/doi/full/10.1056/NEJMp058291)\n\n## History and Development\n\n### Discovery and Early Research\n\nOseltamivir, originally coded as GS4104 by Gilead Sciences, emerged from a targeted medicinal chemistry program in the early 1990s aimed at creating small-molecule inhibitors of influenza neuraminidase, an enzyme essential for viral release from host cells.[](https://pubmed.ncbi.nlm.nih.gov/10702632/) Researchers at Gilead employed structure-based design, leveraging X-ray crystallographic data of neuraminidase to model transition-state mimics that could bind the enzyme's active site with high affinity.[](https://pubmed.ncbi.nlm.nih.gov/10702632/) This approach yielded GS4071 as the potent active carboxylate inhibitor (Ki \u003c1 nM against influenza A and B strains), but its zwitterionic nature limited oral absorption to less than 5% in preclinical models.[](https://pubmed.ncbi.nlm.nih.gov/9517946/)\n\nTo overcome this bioavailability challenge, Gilead synthesized GS4104 as an ethyl ester prodrug of GS4071, facilitating passive diffusion across gastrointestinal membranes before rapid hydrolysis by carboxylesterases in the liver and intestines to release the active metabolite.[](https://pubmed.ncbi.nlm.nih.gov/9517946/) Preclinical pharmacokinetic studies in rodents and ferrets confirmed this activation pathway, with oral dosing of GS4104 achieving systemic exposure of GS4071 equivalent to 35% bioavailability and peak plasma concentrations sufficient for antiviral efficacy (Cmax â‰ˆ0.47 Î¼g/mL in mice).[](https://pubmed.ncbi.nlm.nih.gov/9517946/) In vitro enzymatic assays verified esterase-dependent conversion, with human hepatic carboxylesterase 1 identified as the primary activator, ensuring efficient prodrug metabolism without accumulation of the parent compound.[](https://pubmed.ncbi.nlm.nih.gov/9517946/)\n\nEarly validation included in vitro assays demonstrating GS4071's inhibition of neuraminidase activity across multiple influenza subtypes, reducing plaque formation in cell culture by over 90% at low micromolar concentrations of the prodrug.[](https://pubmed.ncbi.nlm.nih.gov/10702632/) Animal model studies in the mid-1990s, particularly in ferretsâ€”a mammalian surrogate for human influenza pathogenesisâ€”showed that oral GS4104 dosing (e.g., 10 mg/kg) significantly lowered nasal viral titers, shortened fever duration, and mitigated weight loss compared to untreated controls infected with H1N1 or H3N2 strains.[](https://journals.sagepub.com/doi/10.1177/13596535211067598) These findings established causal antiviral effects grounded in neuraminidase blockade, with no evidence of host toxicity at therapeutic doses.[](https://pubmed.ncbi.nlm.nih.gov/10702632/)\n\nIn 1996, Gilead licensed GS4104 to Hoffmann-La Roche for further clinical advancement, retaining royalties while Roche handled large-scale manufacturing and global trials.[](https://www.gilead.com/news/news-details/2005/gilead-and-roche-end-tamiflur-dispute-expanded-collaboration-includes-gilead-role-in-oversight-of-manufacturing-and-commercialization) Phase I/II human trials, initiated in the late 1990s, involved experimentally infected volunteers and confirmed dose-dependent viral clearance (e.g., 1-2 log10 reduction in nasal shedding within 24-48 hours at 100-200 mg twice daily) alongside good tolerability, paving the way for efficacy demonstration without reliance on surrogate endpoints alone.[](https://jamanetwork.com/journals/jama/fullarticle/191957)\n\n### Regulatory Approval and Key Trials\n\nThe U.S. Food and Drug Administration (FDA) approved oseltamivir phosphate, marketed as Tamiflu, on October 27, 1999, for the treatment of uncomplicated acute illness due to influenza A or B virus in adults capable of self-care, based on two pivotal phase III randomized, double-blind, placebo-controlled trials demonstrating reductions in symptom duration.[](https://www.gilead.com/news/news-details/1999/roche-receives-fda-approval-of-tamiflu-first-pill-to-treat-the-most-common-strains-of-influenza-ab)[](https://jamanetwork.com/journals/jama/fullarticle/192425) In these trials, involving over 1,000 naturally infected adults treated within 40 hours of symptom onset, the primary empirical endpoint was the median time to alleviation of seven influenza symptoms (e.g., headache, myalgia, cough), which was shortened by approximately 30 hours (1.3 days) with 75 mg twice-daily oseltamivir compared to placebo (71% vs. 62% alleviation by day 3 in one trial).[](https://jamanetwork.com/journals/jama/fullarticle/192425) Viral titers and shedding were secondary virological endpoints, but approval emphasized clinical symptom relief over surrogates like viral load reduction. The FDA expanded approval to an oral suspension for children aged 1 year and older on December 14, 2000, following supportive pediatric data extrapolated from adult trials and smaller studies showing similar proportional symptom reductions.[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-246_Tamiflu.cfm) Prophylactic use for post-exposure prevention was approved in November 2001, supported by trials in household contacts and immunocompromised adults where oseltamivir reduced influenza incidence by 89-92%.[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021246Orig1s045_021087Orig1s062OtherR.pdf)\n\nThe European Medicines Agency (EMA) granted centralized marketing authorization for oseltamivir on June 20, 2002, for similar indications in adults and children over 1 year, relying on the same core dataset of treatment and prophylaxis trials with consistent empirical outcomes on symptom duration and incidence prevention.[](https://www.ema.europa.eu/en/medicines/human/EPAR/tamiflu) These approvals prioritized clinical endpoints like time-to-alleviation over virological markers, as trials measured patient-reported symptom relief via daily diaries rather than hospitalization or mortality, which were rare events in uncomplicated outpatient populations.[](https://jamanetwork.com/journals/jama/fullarticle/192425)\n\nDuring the 2009 H1N1 influenza pandemic, the FDA issued Emergency Use Authorizations (EUAs) on April 27, 2009, expanding oseltamivir dosing to infants under 1 year and intravenous formulations for hospitalized patients, based on observational data and in vitro susceptibility rather than new large-scale RCTs specific to the strain.[](https://www.federalregister.gov/documents/2009/08/04/E9-18568/authorizations-of-emergency-use-of-certain-antiviral-drugs-zanamivir-and-oseltamivir-phosphate) Governments worldwide stockpiled billions of treatment courses, including over 1 billion doses secured by the U.S. alone, leveraging existing trial evidence of symptom reduction despite gaps in strain-specific efficacy trials at pandemic onset.[](https://www.federalregister.gov/documents/2009/08/04/E9-18568/authorizations-of-emergency-use-of-certain-antiviral-drugs-zanamivir-and-oseltamivir-phosphate) Subsequent amendments through 2010 refined pediatric dosing under EUA, maintaining focus on empirical symptom management in resource-limited settings.[](https://www.federalregister.gov/documents/2010/04/19/2010-8603/amended-authorizations-of-emergency-use-of-certain-antiviral-drugs-zanamivir-and-oseltamivir)\n\n### Data Transparency and Policy Debates\n\nThe Cochrane Collaboration's 2014 systematic review of oseltamivir, based on full clinical study reports from 25 trials involving over 9,000 participants, concluded that the drug shortened symptom duration by about 17 hours in adults but provided no evidence of reducing influenza complications such as pneumonia or transmission to household contacts, contradicting earlier manufacturer claims of broader benefits derived from partial summary data.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3981975/) These findings emerged after sustained pressure from independent researchers and outlets like the BMJ, which from 2009 onward campaigned for Roche to release complete trial data from the 1990s onward, as regulatory summaries had overstated efficacy while omitting key safety and transmission details.[](https://www.bmj.com/tamiflu) Roche finally agreed in April 2013 to provide access to all 77 oseltamivir trials' raw data following this advocacy, revealing discrepancies that highlighted risks of relying on industry-provided summaries prone to selective reporting.[](https://www.bbc.com/news/health-22029708)\n\nGovernment stockpiling policies amplified these transparency issues, with nations expending billions on oseltamivir reserves justified by modeling projections of pandemic utility rather than robust causal evidence from full datasets. The United States allocated over $1.3 billion between 2005 and the early 2010s for approximately 65 million treatment courses, while the United Kingdom spent Â£473 million by 2014 on stockpiles for pandemic preparedness, decisions influenced by pre-2014 partial data suggesting stronger preventive effects against spread.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4375804/) Post-Cochrane analysis indicated these investments lacked empirical support for averting severe outcomes or transmission at scale, prompting critiques of fiscal inefficiency in public health spending driven by alliances between pharmaceutical firms and agencies favoring precautionary models over verified trial outcomes.[](https://www.bbc.com/news/health-26954482)\n\nIn September 2025, the UK government removed seasonal prescribing restrictions on oseltamivir, permitting year-round use by physicians and pharmacists to enhance outbreak response flexibility, a shift from prior flu-season-only protocols amid ongoing debates over the drug's marginal benefits outside confirmed epidemics.[](https://www.gov.uk/government/news/government-to-combat-flu-outbreaks-by-removing-red-tape) This relaxation occurs against evidence from comprehensive reviews questioning routine off-season deployment, as oseltamivir's prophylaxis efficacy remains limited to reducing symptomatic cases by 55% in exposed groups without proven impact on hospitalizations or broader containment.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3981975/) Such policy adjustments underscore persistent tensions between adaptive procurement strategies and the causal uncertainties exposed by delayed data access, with independent analyses emphasizing the need for skepticism toward unverified modeling in antiviral allocation.[](https://www.theguardian.com/business/2014/apr/10/tamiflu-saga-drug-trials-big-pharma)\n\n## Non-Human Applications\n\n### Veterinary Use\n\nOseltamivir has been investigated for off-label use in poultry to mitigate outbreaks of highly pathogenic avian influenza (HPAI), particularly H5N1 strains, with studies demonstrating reduced viral replication and transmission in infected chickens.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11054683/)[](https://www.sciencedirect.com/science/article/abs/pii/S0531513104000214) Systemic administration limits severe morbidity, mortality, and chicken-to-chicken spread of HPAI virus, though efficacy varies by strain pathogenicity.[](https://www.sciencedirect.com/science/article/abs/pii/S0531513104000214) However, resistance has emerged in poultry isolates, such as clade 2.3.4.4b H5N1 viruses exhibiting a 161.4-fold increase in oseltamivir IC50 values due to neuraminidase mutations like H275Y.[](https://www.tandfonline.com/doi/full/10.1080/22221751.2025.2469643)\n\nIn swine models of influenza A virus infection, oseltamivir treatment significantly delays and reduces nasal virus shedding compared to untreated controls, supporting its experimental application against porcine strains.[](https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2022.999507/full) Pharmacokinetic studies in juvenile pigs confirm bioavailability of oseltamivir formulations, with plasma concentrations measurable up to 48 hours post-administration, though metabolic differences from humans may influence dosing requirements.[](https://www.tandfonline.com/doi/abs/10.1080/17576180.2024.2352256)\n\nRegulatory restrictions limit veterinary applications to preserve oseltamivir's efficacy for human use, particularly amid concerns over resistance transfer from animals. In 2006, the U.S. Food and Drug Administration prohibited extralabel use of neuraminidase inhibitors, including oseltamivir, in chickens, turkeys, and ducks due to risks of antiviral resistance development in influenza viruses circulating in poultry flocks.[](https://www.federalregister.gov/documents/2006/03/22/06-2689/new-animal-drugs-adamantane-and-neuraminidase-inhibitor-anti-influenza-drugs-extralabel-animal-drug) This measure addresses potential residue accumulation and cross-species transmission of resistant strains, prioritizing human pandemic preparedness over routine animal prophylaxis.[](https://www.merckvetmanual.com/pharmacology/antiviral-agents/overview-of-antiviral-agents-used-in-animals)\n\n## Current Research and Alternatives\n\n### Emerging Studies\n\nA multicenter cohort study published in *JAMA Network Open* on June 10, 2025, examined oseltamivir treatment versus supportive care in adults hospitalized with seasonal influenza, finding lower in-hospital mortality (3.5% versus 4.9%; adjusted risk difference -1.8%), shorter hospital stays, and reduced 30-day readmission rates among those treated within 2 days of admission.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835158) However, as an observational study using overlap weighting to adjust for confounders, it remains susceptible to unmeasured biases, such as healthier patients receiving antivirals preferentially, and lacks randomization to definitively establish causality.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835158) Similar observational data from 2025 reinforce reduced mortality risks even with delayed oseltamivir initiation beyond 48 hours in older adults, though randomized controlled trials (RCTs) specifically targeting mortality endpoints in hospitalized patients continue to show evidence gaps.[](https://pubmed.ncbi.nlm.nih.gov/39968306/)\n\nRecent analyses have addressed longstanding concerns about neuropsychiatric adverse events in pediatric use, with a *JAMA Neurology* study from August 4, 2025, analyzing over 3 million children and finding no increased risk of such events with oseltamivir treatment for influenza; instead, influenza itself elevated risks, and treatment was linked to decreased severe neuropsychiatric outcomes in subgroup analyses.[](https://jamanetwork.com/journals/jamaneurology/fullarticle/2837165) A September 2025 meta-analysis of observational data further confirmed no association with neuropsychiatric or behavioral events, potentially challenging prior label warnings based on early post-marketing reports, though prospective RCTs in children for these rare endpoints remain limited.[](https://www.jmcp.org/doi/10.18553/jmcp.2025.31.10.1051)\n\nPreclinical research from St. Jude Children's Research Hospital, reported March 17, 2025, tested oseltamivir in mouse models of severe H5N1 avian influenza infection simulating exposure via contaminated bovine milk, revealing limited efficacy in reducing mortality or viral loads during high-dose, systemic disease phases compared to milder models.[](https://www.stjude.org/media-resources/news-releases/2025-medicine-science-news/current-antivirals-likely-less-effective-against-severe-infection-caused-by-bird-flu-in-cows-milk.html) These findings highlight potential vulnerabilities in oseltamivir's neuraminidase inhibition against highly pathogenic strains in severe contexts, underscoring the need for strain-specific RCTs or combination therapies, as susceptibility testing showed retained activity but suboptimal clinical translation in advanced infection.[](https://www.stjude.org/media-resources/news-releases/2025-medicine-science-news/current-antivirals-likely-less-effective-against-severe-infection-caused-by-bird-flu-in-cows-milk.html) Overall, while 2023-2025 data bolster supportive roles for oseltamivir in reducing hospitalization burdens, persistent reliance on non-randomized designs perpetuates uncertainties in mortality benefits and resistance scenarios.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835158)[](https://jamanetwork.com/journals/jamaneurology/fullarticle/2837165)\n\n### Comparative Antivirals\n\nOseltamivir, an oral neuraminidase inhibitor, is compared to other influenza antivirals including zanamivir (inhaled), peramivir (intravenous), and baloxavir marboxil (single-dose oral endonuclease inhibitor). Head-to-head trials and meta-analyses indicate broadly similar clinical efficacy in reducing symptom duration and hospitalization risk across these agents, with differences primarily in administration route, adherence, and resistance emergence.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8363918/)01307-2/fulltext) For uncomplicated outpatient influenza, oseltamivir's five-day oral regimen achieves noninferiority to zanamivir's inhaled delivery in preventing hospitalization or death, though inhalation poses adherence challenges due to device use and patient technique, leading to higher non-persistence rates than oral therapy.[](https://pubmed.ncbi.nlm.nih.gov/35299245/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC5734282/)\n\nZanamivir avoids gastrointestinal side effects common with oseltamivir, such as nausea (affecting up to 10% of users), but its respiratory delivery limits utility in patients with airway compromise and correlates with lower compliance in real-world settings compared to oral oseltamivir.[](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782995) Peramivir, reserved for hospitalized patients unable to tolerate oral intake, demonstrates comparable reductions in hospital length of stay to oseltamivir (low-certainty evidence from network meta-analysis), with a single intravenous dose option providing convenience in acute settings but requiring vascular access.[](https://www.acpjournals.org/doi/10.7326/ANNALS-24-03198-JC)01307-2/fulltext)\n\nBaloxavir offers a single-dose advantage, shortening fever duration by approximately 13 hours more than oseltamivir in some meta-analyses and reducing hospitalization incidence (0.15% vs. 0.37%; risk ratio 2.48), particularly for influenza B.[](https://pubmed.ncbi.nlm.nih.gov/39529764/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC11347862/) However, its monotherapy raises concerns for rapid resistance emergence, as modeling shows potential acceleration of variants under widespread use, contrasting oseltamivir's established but subtype-specific resistance patterns (e.g., H1N1).[](https://academic.oup.com/jid/article/232/Supplement_3/S299/8287909) Baloxavir's higher cost and limited long-term safety data relative to oseltamivir's extensive profile contribute to its selective use.[](https://www.uspharmacist.com/article/comparing-oral-antiviral-agents-for-seasonal-influenza)\n\nGuidelines from the CDC prioritize oseltamivir for outpatients due to its oral bioavailability, pediatric dosing flexibility, and accumulation of empirical evidence, despite no consistent superiority in direct comparisons; alternatives like zanamivir or peramivir are recommended for oseltamivir resistance or contraindications.[](https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html)[](https://www.uspharmacist.com/article/antiviral-recommendations-for-the-2022-2023-influenza-season) This preference reflects practical considerations over marginal efficacy gains, with combination or sequential therapy explored for severe cases but lacking routine endorsement.[](https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html)"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761882182076,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"Tamiflu (oseltamivir phosphate) Information - FDA\",\"description\":\"Sep 11, 2018 Â· Tamiflu (oseltamivir phosphate) is an oral anti-viral drug approved for the treatment of acute, uncomplicated influenza in patients 2 weeks of age and older\",\"url\":\"https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tamiflu-oseltamivir-phosphate-information\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"Oseltamivir - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Oseltamivir is an antiviral medication used to manage acute, uncomplicated influenza A or B in adult and pediatric patients, including neonates older than 2Â ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK539909/\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"Pharmacokinetics of oseltamivir: an oral antiviral for the treatment ...\",\"description\":\"In infected patients, OC binds to and inhibits the active site of the neuraminidase enzymes that are present on all influenza viruses and are essential for theÂ ...Missing:  peer | Show results with:peer\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2835511/\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"Evaluation of Oseltamivir Used to Prevent Hospitalization in ...\",\"description\":\"Jun 12, 2023 Â· In this systematic review and meta-analysis among influenza-infected outpatients, oseltamivir was not associated with a reduced risk of hospitalization.\",\"url\":\"https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2805976\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"Oseltamivir Treatment vs Supportive Care for Seasonal Influenza ...\",\"description\":\"Jun 10, 2025 Â· Oseltamivir treatment was associated with a lower in-hospital mortality risk, earlier discharge, and lower readmission rate, supporting evidence for theÂ ...\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835158\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"The Tamiflu fiasco and lessons learnt - PMC - PubMed Central\",\"description\":\"Pneumonia, hospitalization, and virus transmission were the major concerns with the disease for which benefits have been claimed in various studies. However,Â ...Introduction Â· Oseltamivir Success-Ground... Â· Revelations Of Cochrane...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4375804/\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"Treating Flu with Antiviral Drugs - CDC\",\"description\":\"Sep 11, 2024 Â· Possible side effects vary for each flu antiviral medication. The most common side effects reported for oseltamivir are nausea and vomiting.\",\"url\":\"https://www.cdc.gov/flu/treatment/antiviral-drugs.html\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"Risk of neuropsychiatric adverse events associated with the use of ...\",\"description\":\"Nov 12, 2018 Â· This study found that the short-term use of oseltamivir triggers the incidence of NPAEs. Early monitoring of NPAEs may be required when prescribing oseltamivir.\",\"url\":\"https://academic.oup.com/jac/article/74/2/453/5173728\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"Influenza Antiviral Medications: Summary for Clinicians - CDC\",\"description\":\"Dec 8, 2023 Â· Oral oseltamivir phosphate is approved by the FDA for treatment of acute uncomplicated influenza within 2 days of illness onset in people 14Â ...\",\"url\":\"https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"Oseltamivir: Uses, Interactions, Mechanism of Action - DrugBank\",\"description\":\"Oseltamivir exerts its antiviral activity by inhibiting the activity of the viral neuraminidase enzyme found on the surface of the virus, which prevents buddingÂ ...\",\"url\":\"https://go.drugbank.com/drugs/DB00198\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"Neuraminidase Inhibitors for Influenza\",\"description\":\"Sep 29, 2005 Â· The neuraminidase inhibitors zanamivir and oseltamivir interfere with the release of progeny influenza virus from infected host cells.\u003c|separator|\u003e\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMra050740\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"Structural and Functional Basis of Resistance to Neuraminidase ...\",\"description\":\"Aug 9, 2010 Â· Analysis of NA crystal structures in complex with the substrate sialic acid resulted in the development of zanamivir (1) and oseltamivir (Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2932999/\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489 ...\",\"description\":\"Zanamivir and oseltamivir carboxylate showed NA inhibitory activities with IC50s of 1.40 to 11.5 nM and 1.43 to 3.65 nM, respectively.\",\"url\":\"https://journals.asm.org/doi/10.1128/aac.00333-08\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"Crystal structures of oseltamivir-resistant influenza virus ... - Nature\",\"description\":\"May 14, 2008 Â· We used X-ray crystallography to understand the structural basis for the poorer binding of oseltamivir to the His274Tyr and Asn294Ser mutantÂ ...\",\"url\":\"https://www.nature.com/articles/nature06956\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"Low Penetration of Oseltamivir and Its Carboxylate into ...\",\"description\":\"The limited access of OC to brain is thought to be due to its low lipophilicity leading to low passive diffusion across the blood-brain barrier (BBB). It isÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2565879/\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"Tamiflu (oseltamivir) dosing, indications, interactions, adverse ...\",\"description\":\"Dosage Modifications. Renal impairment. Treatment. CrCl \u003e60 to 90 mL/min: No dosage adjustment necessary; CrCl \u003e30 to 60 mL/min: 30 mg PO BID; CrCl \u003e10 to 30 mLÂ ...\",\"url\":\"https://reference.medscape.com/drug/tamiflu-oseltamivir-342618\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"[PDF] Tamiflu, INN-oseltamivir phosphate - European Medicines Agency\",\"description\":\"... hepatic esterases to the active metabolite (oseltamivir carboxylate). At least 75 % of an oral dose reaches the systemic circulation as the active metabolite.\",\"url\":\"https://www.ema.europa.eu/en/documents/product-information/tamiflu-epar-product-information_en.pdf\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"Neuraminidase inhibitors for preventing and treating influenza in ...\",\"description\":\"Dec 8, 2009 Â· The efficacy of oral oseltamivir against symptomatic laboratory confirmed influenza was 61% (risk ratio 0.39, 95% confidence interval 0.18 toÂ ...Missing:  et | Show results with:et\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/19995812/\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"Clinical practice guidelines for influenza\",\"description\":\"Sep 12, 2024 Â· These updated guidelines provide recommendations on the management of both severe and non-severe influenza and also includes recommendations on the use ofÂ ...\",\"url\":\"https://www.who.int/publications/i/item/9789240097759\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"Generic Tamiflu Availability - Drugs.com\",\"description\":\"Oct 8, 2025 Â· Approval date: December 14, 2000. Strength(s): EQ 12MG BASE/ML (discontinued); Manufacturer: ROCHE Approval date: March 21, 2011. Strength(s):Â ...\",\"url\":\"https://www.drugs.com/availability/generic-tamiflu.html\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"[PDF] oseltamivir label - accessdata.fda.gov\",\"description\":\"See full prescribing information for TAMIFLU. TAMIFLUÂ® (oseltamivir phosphate) capsules, for oral use. TAMIFLUÂ® (oseltamivir phosphate) for oral suspension.\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021087s071%2C021246s054lbl.pdf\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"[PDF] TAMIFLUÂ® (oseltamivir phosphate) capsules, for oral use\",\"description\":\"* Capsules or oral suspension can be used for 30 mg dosing. â€  The recommended duration for post-exposure prophylaxis is at least 10 days and the recommendedÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021087s070lbl%2C%2520021246s053lbl.pdf\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"Effectiveness of oseltamivir in preventing influenza in household ...\",\"description\":\"Results: In contacts of an influenza-positive IC, the overall protective efficacy of oseltamivir against clinical influenza was 89% for individuals (95%Â ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/11176912/\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"Oseltamivir for Influenza Postexposure Prophylaxis\",\"description\":\"Oseltamivir clinical studies have demonstrated efficacy of 7- to 10-day PEP in preventing influenza infections when given within 2 days of exposure to aÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.ajpmonline.org/article/S0749-3797%2809%2900527-3/fulltext\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"Tamiflu Dosage Guide - Drugs.com\",\"description\":\"Dec 11, 2024 Â· Dosage modifications are recommended in adults with an estimated creatinine clearance less than or equal to 60 mL per minute. Capsules or oralÂ ...\",\"url\":\"https://www.drugs.com/dosage/tamiflu.html\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"Antivirals for post-exposure prophylaxis of influenza - The Lancet\",\"description\":\"Aug 24, 2024 Â· Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001; 285:748-754. Crossref.\",\"url\":\"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2901357-6/fulltext\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"[PDF] Maximizing the Value of Drug Stockpiles for Pandemic Influenza\",\"description\":\"More than 70 governments have placed orders for Tamiflu, and at least 220 million treatment courses have been stockpiled since 2003 at a cost of $6.9 billion (1)Â ...\",\"url\":\"https://stacks.cdc.gov/view/cdc/17978/cdc_17978_DS1.pdf?\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"Original article Efficacy and safety of oral oseltamivir for influenza ...\",\"description\":\"Conclusions: Oseltamivir prophylaxis is generally well- tolerated and may reduce culture- or PCR-confirmed influenza incidence in transplant recipients.\",\"url\":\"https://journals.sagepub.com/doi/pdf/10.3851/IMP2192\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"Influenza prevention and treatment in transplant recipients and ... - NIH\",\"description\":\"Seasonal prophylaxis with oseltamivir may be an alternative to vaccination in patients who are predicted to have a poor response to vaccine. Therapy withÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6492654/\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"Recommendations for Obstetric Health Care Providers Related to ...\",\"description\":\"Sep 15, 2022 Â· Oral oseltamivir, zanamivir, and peramivir are \\\"Pregnancy Category C\\\" medications, indicating that controlled clinical studies have not beenÂ ...Missing:  2025 | Show results with:2025\",\"url\":\"https://www.cdc.gov/flu/hcp/antivirals/treatment_obstetric.html\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"Clinical Effectiveness and Safety of Antivirals for Influenza in ...\",\"description\":\"Observational data show a reduction of severe outcomes when pregnant and postpartum women are treated with oseltamivir and other neuraminidase inhibitorsÂ ...\",\"url\":\"https://academic.oup.com/ofid/article/8/6/ofab138/6179259\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"Safety of Oseltamivir in Pregnancy A Review of Preclinical and ...\",\"description\":\"Aug 30, 2025 Â· No adverse effects on pregnant women or fetuses have been observed as a result of treatment with oseltamivir during pregnancy (109, 110) . ...\u003c|separator|\u003e\",\"url\":\"https://www.researchgate.net/publication/45268377_Safety_of_Oseltamivir_in_Pregnancy_A_Review_of_Preclinical_and_Clinical_Data\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"Oseltamivir Reduces 30-Day Mortality in Older Adults With Influenza\",\"description\":\"Feb 3, 2025 Â· A total of 395 patients were hospitalized for \u003e30 days. The overall mortality rate was 8.32 per 1000 person-days, with 53.9% of the deathsÂ ...Missing:  high- real- world JAMA\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39968306/\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"Antiviral Medications for Treatment of Nonsevere Influenza\",\"description\":\"Jan 13, 2025 Â· Oseltamivir had little or no effect on mortality and admission to hospital, likely had no important effect on time to alleviation of symptoms,Â ...Missing:  elderly | Show results with:elderly\",\"url\":\"https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2829156\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"Neuraminidase inhibitors for preventing and treating influenza in ...\",\"description\":\"Apr 10, 2014 Â· Treatment of adults with oseltamivir had no significant effect on hospitalisations: risk difference (RD) 0.15% (95% CI â€0.78 to 0.91). There wasÂ ...Missing:  efficacy | Show results with:efficacy\",\"url\":\"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008965.pub4/full\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"Neuraminidase Inhibitors For Treatment of Influenza - TheNNT\",\"description\":\"Treatment: In adults, oseltamivir reduced time to first alleviation of symptoms by 16.8 hours (95% CI 8.4 to 25.1). Zanamivir reduced the time to firstÂ ...\u003c|separator|\u003e\",\"url\":\"https://thennt.com/nnt/neuraminidase-inhibitors-treatment-influenza/\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"Effects of oseltamivir treatment on duration of clinical illness ... - NIH\",\"description\":\"Index subjects who had taken oseltamivir within 24 hours of symptom onset experienced a 44% reduction in time to alleviation of all signs and symptoms, withÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2840043/\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"Study of the Impact of Oseltamivir on the Risk for Pneumonia and ...\",\"description\":\"This study shows that treatment of influenza patients with oseltamivir significantly reduces the risk for influenza-related complications and hospitalization.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2491667/\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"Antiviral Treatment for Patients Hospitalized with 2009 Pandemic ...\",\"description\":\"Nov 18, 2009 Â· Starting treatment with a neuraminidase inhibitor within 2 days after symptom onset was significantly associated with a lower risk of ICUÂ ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMopv0910738\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"Association of Early Oseltamivir With Improved Outcomes in ...\",\"description\":\"Sep 19, 2022 Â· Early use of oseltamivir in hospitalized children was associated with shorter hospital stay and lower odds of 7-day readmission, ICU transfer, ECMO use, andÂ ...Missing:  elderly | Show results with:elderly\",\"url\":\"https://jamanetwork.com/journals/jamapediatrics/fullarticle/2796162\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"Large study shows Tamiflu cut H1N1 pandemic deaths - CIDRAP\",\"description\":\"Mar 19, 2014 Â· Overall, treatment with neuraminidase inhibitors, primarily oseltamivir, reduced the risk of death by 19% compared with no treatment. However,Â ...\",\"url\":\"https://www.cidrap.umn.edu/h1n1-2009-pandemic-influenza/large-study-shows-tamiflu-cut-h1n1-pandemic-deaths\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection\",\"description\":\"Early therapy with oseltamivir in patients with 2009 H1N1 virus infection may reduce the duration of hospitalization and the risk of progression to severeÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMra1000449\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"Survival biases lead to flawed conclusions in observational ...\",\"description\":\"Several observational studies reported that Oseltamivir (Tamiflu) reduced mortality in infected and hospitalized patients.Missing:  swine | Show results with:swine\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0895435616302669\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"Effect of oseltamivir on mortality in patients with 2009A/H1N1 influenza\",\"description\":\"After taking account of time-dependent bias, potential confounding variables, and the competing risk of hospital discharge, analysis of the IPD showedÂ ...Missing:  swine flu\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK363115/\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"No effect of oseltamivir on mortality in patients with 2009A/H1N1 ...\",\"description\":\"We found insufficient evidence from 30 observational studies to support oseltamivir having a protective effect on 2009A/H1N1 influenza patients for mortality.Missing:  factors | Show results with:factors\",\"url\":\"https://www.cebm.net/announcement/no-effect-oseltamivir-mortality-patients-2009ah1n1-influenza/\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"Effectiveness of neuraminidase inhibitors in reducing mortality in ...\",\"description\":\"Neuraminidase inhibitors were widely used during the 2009â€“10 influenza A H1N1 pandemic, but evidence for their effectiveness in reducing mortality isÂ ...\",\"url\":\"https://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2814%2970041-4/abstract\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"Interim Guidance on the Use of Antiviral Medications for Treatment ...\",\"description\":\"Jul 3, 2025 Â· Outpatients. Initiation of antiviral treatment with oseltamivir is recommended as soon as possible for symptomatic outpatients who areÂ ...\",\"url\":\"https://www.cdc.gov/bird-flu/hcp/clinicians-evaluating-patients/interim-guidance-treatment-humans.html\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"'Exceptionally rare' mutation on H5N1 virus in Canada ... - CIDRAP\",\"description\":\"Feb 21, 2025 Â· Researchers at the Canada Food Inspection Agency (CFIA) describe their discovery of a mutated H5N1 avian flu strain resistant to the antiviral drug oseltamivirÂ ...\",\"url\":\"https://www.cidrap.umn.edu/avian-influenza-bird-flu/exceptionally-rare-mutation-h5n1-virus-canada-tied-antiviral-drug\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"Antiviral Susceptibility of Influenza A(H5N1) Clade 2.3.2.1c and 2.3 ...\",\"description\":\"Among the NA inhibitors, oseltamivir is the most widely used influenza antiviral (16,20). Of note, most seasonal influenza A(H1N1) viruses circulating globallyÂ ...\",\"url\":\"https://wwwnc.cdc.gov/eid/article/31/4/24-1820_article\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"[PDF] Summary of neuraminidase (NA) amino acid substitutions assessed ...\",\"description\":\"Sep 18, 2024 Â· Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. J Infect Public Health 2:74-80. 57. Creanga A, Hang NLKÂ ...\",\"url\":\"https://cdn.who.int/media/docs/default-source/influenza/laboratory---network/quality-assurance/human-nai-marker-table_for-publication_final_20240918.pdf?sfvrsn=c6d153ec_3\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"Debate Regarding Oseltamivir Use for Seasonal and Pandemic ...\",\"description\":\"Two prospective observational studies of hospitalized patients with laboratory-confirmed seasonal influenza have shown oseltamivir treatment decreases the riskÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4880079/\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"Debate Regarding Oseltamivir Use for Seasonal and Pandemic ...\",\"description\":\"May 16, 2016 Â· The Cochrane systematic review, which focused only on an intention-to-treat analysis, confirmed that oseltamivir reduced symptom duration in theÂ ...\",\"url\":\"https://wwwnc.cdc.gov/eid/article/22/6/15-1037_article\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"Effectiveness of oseltamivir on disease progression and viral RNA ...\",\"description\":\"Sep 28, 2010 Â· 2009 H1N1 might be shed longer than seasonal influenza virus. Treatment with oseltamivir was associated with a significantly reduced developmentÂ ...\",\"url\":\"https://www.bmj.com/content/341/bmj.c4779\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"Oseltamivir for influenza in adults and children: systematic review of ...\",\"description\":\"Apr 9, 2014 Â· The evidence we have presented shows that oseltamivir has symptom relieving effects. This may also explain the observed effect on investigatorÂ ...Review Protocol Amendments... Â· Results Â· Discussion\",\"url\":\"https://www.bmj.com/content/348/bmj.g2545\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"Risk of bias in industry-funded oseltamivir trials: comparison of core ...\",\"description\":\"Sep 30, 2014 Â· We used the Cochrane risk of bias tool to assess and compare risk of bias in 14 oseltamivir trials (reported in 10 clinical study reports)Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4179405/\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"What the Tamiflu saga tells us about drug trials and big pharma\",\"description\":\"Apr 10, 2014 Â· That is a scandal because the UK government spent Â£0.5bn stockpiling this drug in the hope that it would help prevent serious side-effects fromÂ ...Missing:  causal hoc\",\"url\":\"https://www.theguardian.com/business/2014/apr/10/tamiflu-saga-drug-trials-big-pharma\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"Experts say recent network meta-analysis won't change flu antiviral ...\",\"description\":\"Jan 22, 2025 Â· A network meta-analysis of 73 trials comparing the effectiveness of flu antivirals suggests that only baloxavir (Xofluza) may be better than standard care or aÂ ...\",\"url\":\"https://www.cidrap.umn.edu/influenza-general/experts-say-recent-network-meta-analysis-wont-change-flu-antiviral-practices\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"Oseltamivir for Treatment of Influenza in Healthy Adults: Pooled Trial ...\",\"description\":\"Cost per influenza-day averted with oseltamivir on formulary is $49 (95% CI 31â€“107) and the cost per QALY is $57,863 (95% CI $48,919â€“ $70,149). Results areÂ ...\",\"url\":\"https://www.valueinhealthjournal.com/article/S1098-3015%2810%2960141-6/fulltext\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"Cost-effectiveness of adding oseltamivir to primary care for influenza ...\",\"description\":\"Sep 22, 2022 Â· In adults/adolescents with relevant comorbidity, oseltamivir is cost-effective up to WTP values of â‚¬44,558 from the healthcare payers'Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10290610/\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"Antiviral Adverse Events | Influenza (Flu) - CDC\",\"description\":\"Nausea and vomiting were reported more frequently among adults receiving oral oseltamivir for treatment (nausea without vomiting, approximately 10%; vomiting,Â ...Missing:  incidence | Show results with:incidence\",\"url\":\"https://www.cdc.gov/flu/hcp/antivirals/antiviral-adverse-events.html\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"[PDF] medical review(s) - accessdata.fda.gov\",\"description\":\"Oct 25, 1999 Â· The symptom of fatigue was not relieved sooner; therefore there was no overall difference between treatment groups with respect to the time toÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21087_Tamiflu_medr_P1.pdf\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"Oseltamivir Side Effects: Common, Severe, Long Term - Drugs.com\",\"description\":\"Sep 24, 2025 Â· Side effects with similar or higher incidence among placebo patients included fatigue, pyrexia, influenza-like illness, and pain in limb.\",\"url\":\"https://www.drugs.com/sfx/oseltamivir-side-effects.html\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"Early administration of oral oseltamivir increases the benefits of ...\",\"description\":\"When oseltamivir was taken with food, the tolerability was enhanced. The overall discontinuation rate was low (1.8%).\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/12493796/\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Anaphylaxis after Oseltamivir (TamifluÂ®) therapy in a patient with ...\",\"description\":\"Aug 7, 2025 Â· ... Oseltamivir, used in influenza, causes rare hypersensitivity reactions although close monitoring of patients is important as 2 cases withÂ ...\",\"url\":\"https://www.researchgate.net/publication/5663579_Anaphylaxis_after_Oseltamivir_TamifluR_therapy_in_a_patient_with_sensitization_to_star_anise_and_celery-carrot-mugwort-spice_syndrome\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"Case Report Possible Oseltamivir-Induced Angioedema in a Patient ...\",\"description\":\"hypersensitivity to oseltamivir by causing an increase in pre-existing plasma cells to release IgE, which eventually induces anaphylaxis.11 A significantÂ ...\",\"url\":\"https://www.ovid.com/journals/hpha/pdf/10.1310/hpj4608-591~possible-oseltamivir-induced-angioedema-in-a-patient-with\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"The real-world safety of oseltamivir and baloxavir marboxil in children\",\"description\":\"Jul 10, 2024 Â· A total of 464 reports of AEs to oseltamivir as the â€œprimary suspect (PS)â€ and 429 reports of AEs to baloxavir marboxil as the â€œPSâ€ wereÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11266138/\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"Oseltamivir-Current Dosing Recommendations Reduce the ...\",\"description\":\"Oseltamivir is renally cleared and dose reductions are advised for patients with renal impairment. The purpose of this review was to determine whether theseÂ ...Missing:  toxicity overdose\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/32947554/\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"[PDF] TAMIFLUÂ® (oseltamivir phosphate) - accessdata.fda.gov\",\"description\":\"Oseltamivir is an antiviral drug [see Microbiology (12.4)]. 12.3. Pharmacokinetics. Absorption and Bioavailability. Oseltamivir is readily absorbed from theÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021087s062lbl.pdf\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"Can Tamiflu (Oseltamivir) cause Acute Kidney Injury (AKI) after 4 ...\",\"description\":\"Feb 8, 2025 Â· There is evidence to suggest that oseltamivir can cause Acute Kidney Injury (AKI) in certain patients, particularly those with pre-existingÂ ...Missing:  overdose | Show results with:overdose\",\"url\":\"https://www.droracle.ai/articles/1882/can-tamiflu-affect-kidneys-causing-aki-after-4-days-\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"Flu Antiviral Drug Interactions - CDC Archive\",\"description\":\"For example, co-administration of oseltamivir and probenecid resulted in reduced clearance of oseltamivir carboxylate by approximately 50% and a correspondingÂ ...\",\"url\":\"https://archive.cdc.gov/www_cdc_gov/flu/professionals/antivirals/antiviral-drug-interactions.htm\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"Probenecid with Oseltamivir for Human Influenza A (H5N1) Virus ...\",\"description\":\"Coadministration of oseltamivir and probenecid has resulted in a reduction in the clearance of oseltamivir by approximately 50 percent and a correspondingÂ ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMc052951\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"Pharmacokinetics and Tolerability of Oseltamivir Combined ... - NIH\",\"description\":\"Prior studies have indicated that there is no significant interaction of probenecid with hepatic P450 isoenzymes. However, numerous medications are renallyÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2533494/\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"The mechanisms of suddenâ€onset type adverse reactions to ...\",\"description\":\"However, serious neuropsychiatric adverse reactions to oseltamivir, including sudden death and abnormal behaviours leading to accidental death, were reportedÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5201449/\",\"favicon\":\"\"},{\"id\":\"74\",\"title\":\"Tamiflu Findings Raise Questions About Drug Label Warning for Kids\",\"description\":\"Aug 5, 2025 Â· \\\"In fact, oseltamivir treatment lowered the risk of neuropsychiatric events in children by about 50%.\\\" The findings raise questions aboutÂ ...\",\"url\":\"https://www.medpagetoday.com/neurology/generalneurology/116827\",\"favicon\":\"\"},{\"id\":\"75\",\"title\":\"[PDF] Psychiatric Adverse Events Associated with Oseltamivir\",\"description\":\"Jun 24, 2025 Â· Re-analysis revealed no statisti- cally significant difference in psychiatric adverse events between dose groups in each study without positiveÂ ...\",\"url\":\"https://www.rescp.org/journal/download_pdf.php?doi=10.59931/rcp.25.0007\",\"favicon\":\"\"},{\"id\":\"76\",\"title\":\"Oseltamivir use and severe abnormal behavior in Japanese children ...\",\"description\":\"Aug 24, 2017 Â· Abnormal behavior Type A was more likely to develop up to approximately 30 times during the period between the initial intake of oseltamivirÂ ...Missing:  meta- no\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/28818475/\",\"favicon\":\"\"},{\"id\":\"77\",\"title\":\"Influenza With and Without Oseltamivir Treatment ... - JAMA Network\",\"description\":\"Aug 4, 2025 Â· During influenza periods, treatment with oseltamivir was associated with a reduced risk of serious neuropsychiatric events compared withÂ ...\",\"url\":\"https://jamanetwork.com/journals/jamaneurology/fullarticle/2837165\",\"favicon\":\"\"},{\"id\":\"78\",\"title\":\"Influenza With and Without Oseltamivir Treatment and ... - PubMed\",\"description\":\"Aug 4, 2025 Â· In this cohort study, oseltamivir treatment during influenza episodes was associated with a reduced risk of serious neuropsychiatric events.Missing:  effects | Show results with:effects\u003c|separator|\u003e\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/40758339/\",\"favicon\":\"\"},{\"id\":\"79\",\"title\":\"Associations of oseltamivir with neuropsychiatric and behavioral ...\",\"description\":\"Sep 26, 2025 Â· Oseltamivir may still be used as the first-line pharmacotherapy for patients with influenza infections. These findings may help reduce barriersÂ ...\",\"url\":\"https://www.jmcp.org/doi/10.18553/jmcp.2025.31.10.1051\",\"favicon\":\"\"},{\"id\":\"80\",\"title\":\"Associations of oseltamivir with neuropsychiatric and behavioral ...\",\"description\":\"This meta-analysis provides robust evidence that oseltamivir is not associated with increased risks of neuropsychiatric events and may offer protective effectsÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12467762/\",\"favicon\":\"\"},{\"id\":\"81\",\"title\":\"Flu virus triggers neuropsychiatric symptoms not the medication\",\"description\":\"Aug 4, 2025 Â· Influenza itself was associated with an increase in neuropsychiatric events compared to children with no influenza, regardless of oseltamivirÂ ...\",\"url\":\"https://www.news-medical.net/news/20250804/Flu-virus-triggers-neuropsychiatric-symptoms-not-the-medication.aspx\",\"favicon\":\"\"},{\"id\":\"82\",\"title\":\"Influenza, not Tamiflu, may raise risk of neuropsychiatric events in kids\",\"description\":\"Aug 5, 2025 Â· â€œIn fact, oseltamivir treatment seems to prevent neuropsychiatric events rather than cause them.â€ Related news.Missing:  effects | Show results with:effects\",\"url\":\"https://www.cidrap.umn.edu/influenza-general/influenza-not-tamiflu-may-raise-risk-neuropsychiatric-events-kids\",\"favicon\":\"\"},{\"id\":\"83\",\"title\":\"Influenza neuraminidase mutations and resistance to ... - NIH\",\"description\":\"Nov 12, 2024 Â· Neuraminidase mutations conferring resistance to oseltamivir ... H275Y/I223R mutation from a child after prolonged treatment with oseltamivir.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11600549/\",\"favicon\":\"\"},{\"id\":\"84\",\"title\":\"Detection and management of antiviral resistance for influenza viruses\",\"description\":\"... resistance in that viral context is the H275Y neuraminidase mutation (N1 numbering). ... mutations that enhance surface expression of an oseltamivirÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6499333/\",\"favicon\":\"\"},{\"id\":\"85\",\"title\":\"Tamiflu - Oseltamivir Resistance - News-Medical\",\"description\":\"The principal difference is that mutations in hemagglutinin confer resistance ... (H275Y) of the neuraminidase gene, which is the most commonly reported mutation.\",\"url\":\"https://www.news-medical.net/health/Tamiflu-Oseltamivir-Resistance.aspx\",\"favicon\":\"\"},{\"id\":\"86\",\"title\":\"Influenza neuraminidase inhibitors: antiviral action and mechanisms ...\",\"description\":\"Dec 28, 2012 Â· One of these patients contained a mixed population of wild-type virus and viruses with H274Y or N294S mutations. The N294S mutation also appearsÂ ...\",\"url\":\"https://onlinelibrary.wiley.com/doi/10.1111/irv.12047\",\"favicon\":\"\"},{\"id\":\"87\",\"title\":\"Mutation-induced spatial differences in neuraminidase structure and ...\",\"description\":\"Besides the mutations at position 275 and 119, the N294S is another common mutation with observably reduced susceptibility to oseltamivir. The oseltamivir-Â ...\",\"url\":\"https://cpb.iphy.ac.cn/article/2018/1919/cpb_27_1_018704.html\",\"favicon\":\"\"},{\"id\":\"88\",\"title\":\"Influenza treatment and prophylaxis with neuraminidase inhibitors\",\"description\":\"The N294S mutation leads to decreased susceptibility to both zanamivir and oseltamivir and is seen primarily in N1 subtypes. I223R and K mutations can causeÂ ...\",\"url\":\"https://www.tandfonline.com/doi/full/10.2147/IDR.S36601\",\"favicon\":\"\"},{\"id\":\"89\",\"title\":\"Mechanisms to Reduce Influenza's Sensitivity to Oseltamivir - PMC\",\"description\":\"[26], the reported oseltamivir-resistant mutations in neuraminidase had associated fitness costs that often required compensatory, fitness-enhancing mutationsÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4886345/\",\"favicon\":\"\"},{\"id\":\"90\",\"title\":\"Fitness Costs for Influenza B Viruses Carrying Neuraminidase ...\",\"description\":\"Our results confirmed that four NA substitutions reduced inhibition of influenza B virus by oseltamivir, and three (E119A, D198Y, and R371K) conferred highlyÂ ...\",\"url\":\"https://journals.asm.org/doi/10.1128/aac.02628-13\",\"favicon\":\"\"},{\"id\":\"91\",\"title\":\"Epistatic interactions between neuraminidase mutations facilitated ...\",\"description\":\"Oct 9, 2014 Â· As the NA H275Y mutation is associated with oseltamivir resistance ... neuraminidase mutations on viral fitness of the H275Y oseltamivirÂ ...\",\"url\":\"https://www.nature.com/articles/ncomms6029\",\"favicon\":\"\"},{\"id\":\"92\",\"title\":\"Predicting Permissive Mutations That Improve the Fitness of A(H1N1 ...\",\"description\":\"Jul 14, 2022 Â· These changes often come at a fitness cost; however, it is known that permissive mutations in the viral NA can overcome this cost.\",\"url\":\"https://journals.asm.org/doi/10.1128/jvi.00918-22\",\"favicon\":\"\"},{\"id\":\"93\",\"title\":\"A 15-year study of neuraminidase mutations and the increasing of ...\",\"description\":\"Jun 26, 2025 Â· A work conducted among 2014â€“2015 and 2018â€“2019 influenza seasons revealed a 0.5â€“1.8 % prevalence of resistance mutations in A(H1N1)pdm09, veryÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12270646/\",\"favicon\":\"\"},{\"id\":\"94\",\"title\":\"[PDF] Influenza 2025 Review: Antigenic Trends, Vaccine Impact, and ...\",\"description\":\"May 12, 2025 Â· However, the emergence of oseltamivir- resistant A/H1N1pdm09 strains (~2.4%) and persistent inequities in vaccine access underscore the need forÂ ...\",\"url\":\"https://www.health-providers.ir/article_220683_899673f3e0c831ce455365d9df071d69.pdf\",\"favicon\":\"\"},{\"id\":\"95\",\"title\":\"Multicountry Spread of Influenza A(H1N1)pdm09 Viruses with ... - CDC\",\"description\":\"Jun 12, 2024 Â· In addition to H275Y, many NA substitutions in N1 subtype viruses are suspected of reducing oseltamivir susceptibility (5). Although there areÂ ...Missing:  S247R | Show results with:S247R\",\"url\":\"https://wwwnc.cdc.gov/eid/article/30/7/24-0480_article\",\"favicon\":\"\"},{\"id\":\"96\",\"title\":\"Antiviral Therapy for HPAI and Reported Oseltamivir Resistance in ...\",\"description\":\"In November 2024, an oseltamivir-resistant HPAI H5N1 virus (bearing the H275Y mutation) was detected from domestic poultry in a geographically restricted areaÂ ...Missing:  milk- | Show results with:milk-\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12253934/\",\"favicon\":\"\"},{\"id\":\"97\",\"title\":\"Oseltamivir Resistance during Treatment of Influenza A (H5N1 ...\",\"description\":\"Dec 22, 2005 Â· These observations suggest that resistance can emerge during the currently recommended regimen of oseltamivir therapy and may be associated withÂ ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa054512\",\"favicon\":\"\"},{\"id\":\"98\",\"title\":\"Influenza Antiviral Drug Resistance - CDC\",\"description\":\"Oct 25, 2022 Â· Influenza viruses can become less susceptible to antiviral drugs during or after antiviral treatment or emerge spontaneously.\",\"url\":\"https://www.cdc.gov/flu/treatment/antiviralresistance.html\",\"favicon\":\"\"},{\"id\":\"99\",\"title\":\"\",\"description\":\"\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12537536/\",\"favicon\":\"\"},{\"id\":\"100\",\"title\":\"Critical updates in the 2024 influenza clinical practice guidelines of ...\",\"description\":\"The updated guidelines recommend oseltamivir for the treatment of severe influenza but do not recommend peramivir. However, several points of caution are noted.\",\"url\":\"https://journals.lww.com/idi/fulltext/2025/07000/critical_updates_in_the_2024_influenza_clinical.2.aspx\",\"favicon\":\"\"},{\"id\":\"101\",\"title\":\"A Model-based Assessment of Oseltamivir Prophylaxis Strategies to ...\",\"description\":\"If resistance to oseltamivir was increased, both prophylaxis strategies became less efficacious and efficient, but postexposure prophylaxis posed a lowerÂ ...\",\"url\":\"https://wwwnc.cdc.gov/eid/article/15/10/08-1129_article\",\"favicon\":\"\"},{\"id\":\"102\",\"title\":\"Clinical Implications of Antiviral Resistance in Influenza - MDPI\",\"description\":\"On-going surveillance data on seasonal influenza virus strains show that resistance rate to oseltamivir is generally low (1%â€“3%), and resistance to zanamivirÂ ...\",\"url\":\"https://www.mdpi.com/1999-4915/7/9/2850\",\"favicon\":\"\"},{\"id\":\"103\",\"title\":\"Oseltamivir Treatment for Influenza During the Flu Season of 2018 ...\",\"description\":\"May 9, 2022 Â· No effectiveness with oseltamivir therapy was observed in the outcomes of hospitalization frequency, and the duration of fever and cough.\",\"url\":\"https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.865001/full\",\"favicon\":\"\"},{\"id\":\"104\",\"title\":\"Antiviral Susceptibility Influenza - World Health Organization (WHO)\",\"description\":\"The need for surveillance of antiviral susceptibility of influenza viruses has grown in recent years. The laboratory methodologies described below have beenÂ ...\",\"url\":\"https://www.who.int/teams/global-influenza-programme/laboratory-network/quality-assurance/antiviral-susceptibility-influenza\",\"favicon\":\"\"},{\"id\":\"105\",\"title\":\"Laboratory Methods for Monitoring Influenza Antiviral Resistance\",\"description\":\"Oct 17, 2025 Â· Laboratory methodologies for testing influenza viruses' antiviral susceptibility have been developed by the WHO-AVWG and can be found on the WHOÂ ...\",\"url\":\"https://academic.oup.com/jid/article/232/Supplement_3/S273/8287901\",\"favicon\":\"\"},{\"id\":\"106\",\"title\":\"Understanding the Impact of Resistance to Influenza Antivirals\",\"description\":\"Feb 10, 2021 Â· Here, we provide an overview of influenza antiviral resistance in context, exploring the key concepts underlying its development and clinical impact.\",\"url\":\"https://journals.asm.org/doi/10.1128/cmr.00224-20\",\"favicon\":\"\"},{\"id\":\"107\",\"title\":\"Oseltamivir Resistance â€” Disabling Our Influenza Defenses\",\"description\":\"Dec 22, 2005 Â· Misuse of the drug could rob us of the advantages that neuraminidase inhibitors provide, by favoring the emergence of oseltamivir-resistant influenza virus.\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMp058291\",\"favicon\":\"\"},{\"id\":\"108\",\"title\":\"Discovery and development of GS 4104 (oseltamivir) - PubMed\",\"description\":\"This article will summarize the design, discovery, and development of oseltamivir as an oral therapeutic to treat influenza infection.Missing:  synthesis 1993\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/10702632/\",\"favicon\":\"\"},{\"id\":\"109\",\"title\":\"Identification of GS 4104 as an orally bioavailable prodrug ... - PubMed\",\"description\":\"In contrast, GS 4104, the ethyl ester prodrug of GS 4071, exhibited good oral bioavailability (35%) as GS 4071 and high Cmaxs of GS 4071 (Cmax = 0.47 microg/ml)Â ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/9517946/\",\"favicon\":\"\"},{\"id\":\"110\",\"title\":\"Discovery and development of oseltamivir at Gilead Sciences\",\"description\":\"May 1, 2022 Â· Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr Med Chem 2000; 7:663â€“672Â ...\",\"url\":\"https://journals.sagepub.com/doi/10.1177/13596535211067598\",\"favicon\":\"\"},{\"id\":\"111\",\"title\":\"Gilead and Roche End Tamiflu(R) Dispute; Expanded Collaboration ...\",\"description\":\"Tamiflu, the only oral antiviral for the treatment and prevention of influenza A and B, was invented by Gilead and licensed to Roche in 1996. The companiesÂ ...\",\"url\":\"https://www.gilead.com/news/news-details/2005/gilead-and-roche-end-tamiflur-dispute-expanded-collaboration-includes-gilead-role-in-oversight-of-manufacturing-and-commercialization\",\"favicon\":\"\"},{\"id\":\"112\",\"title\":\"Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental ...\",\"description\":\"Oct 6, 1999 Â· Objective To determine the safety, tolerability, and antiviral activity of oral neuraminidase inhibitor oseltamivir (GS4104/Ro64-0796) forÂ ...\u003c|separator|\u003e\",\"url\":\"https://jamanetwork.com/journals/jama/fullarticle/191957\",\"favicon\":\"\"},{\"id\":\"113\",\"title\":\"Roche Receives FDA Approval Of TAMIFLUâ„¢, First Pill To Treat The ...\",\"description\":\"Roche Receives FDA Approval Of TAMIFLUâ„¢, First Pill To Treat The Most Common Strains Of Influenza (A\u0026B) Â· NUTLEY, N.J. -- October 27, 1999. Hoffmann-La Roche IncÂ ...\",\"url\":\"https://www.gilead.com/news/news-details/1999/roche-receives-fda-approval-of-tamiflu-first-pill-to-treat-the-most-common-strains-of-influenza-ab\",\"favicon\":\"\"},{\"id\":\"114\",\"title\":\"Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir ...\",\"description\":\"Feb 23, 2000 Â· Oseltamivir was generally well tolerated in this study, although nausea and emesis occurred more frequently in treated individuals than in thoseÂ ...\",\"url\":\"https://jamanetwork.com/journals/jama/fullarticle/192425\",\"favicon\":\"\"},{\"id\":\"115\",\"title\":\"Drug Approval Package: Tamiflu (Oseltamivir Phosphate) NDA ...\",\"description\":\"Tamiflu (Oseltamivir Phosphate) Oral Suspension Company: Hoffmann-La Roche Inc. Application No.: 021246. Approval Date: 12/14/2000 Â· Approval Letter(s) (PDF).\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-246_Tamiflu.cfm\",\"favicon\":\"\"},{\"id\":\"116\",\"title\":\"[PDF] 021246Orig1s045 and 021087Orig1s062 - accessdata.fda.gov\",\"description\":\"Dec 19, 2012 Â· TAMIFLU (oseltamivir phosphate) capsules were originally approved October 27, 1999 for the treatment of uncomplicated acute illness due toÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021246Orig1s045_021087Orig1s062OtherR.pdf\",\"favicon\":\"\"},{\"id\":\"117\",\"title\":\"Tamiflu | European Medicines Agency (EMA)\",\"description\":\"Tamiflu is an antiviral medicine used to treat or prevent influenza (flu). Tamiflu cannot replace flu vaccination, and its use should be based on officialÂ ...\",\"url\":\"https://www.ema.europa.eu/en/medicines/human/EPAR/tamiflu\",\"favicon\":\"\"},{\"id\":\"118\",\"title\":\"Authorizations of Emergency Use of Certain Antiviral Drugs ...\",\"description\":\"Aug 4, 2009 Â· On April 26, 2009, CDC requested and, on April 27, 2009, FDA issued EUAs for zanamivir inhalation powder and certain oseltamivir phosphateÂ ...\",\"url\":\"https://www.federalregister.gov/documents/2009/08/04/E9-18568/authorizations-of-emergency-use-of-certain-antiviral-drugs-zanamivir-and-oseltamivir-phosphate\",\"favicon\":\"\"},{\"id\":\"119\",\"title\":\"Amended Authorizations of Emergency Use of Certain Antiviral ...\",\"description\":\"Apr 19, 2010 Â· I have concluded, pursuant to section 564(d)(1) of the Act, that the scope of this authorization is limited to the use of authorized oseltamivirÂ ...\",\"url\":\"https://www.federalregister.gov/documents/2010/04/19/2010-8603/amended-authorizations-of-emergency-use-of-certain-antiviral-drugs-zanamivir-and-oseltamivir\",\"favicon\":\"\"},{\"id\":\"120\",\"title\":\"Oseltamivir for influenza in adults and children: systematic review of ...\",\"description\":\"Apr 10, 2014 Â· In treatment studies it also modestly reduces the time to first alleviation of symptoms, but it causes nausea and vomiting and increases theÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3981975/\",\"favicon\":\"\"},{\"id\":\"121\",\"title\":\"Tamiflu campaign - The BMJ\",\"description\":\"TAMIFLU has not been shown to prevent such complications.â€ The majority of Roche's Phase III treatment trials were unpublished a decade after completion.\",\"url\":\"https://www.bmj.com/tamiflu\",\"favicon\":\"\"},{\"id\":\"122\",\"title\":\"Roche agrees to release all trial data on Tamiflu drug - BBC News\",\"description\":\"Apr 4, 2013 Â· The drug company Roche, which makes Tamiflu, has announced it will give researchers access to all its trial data for the influenza drug,Â ...Missing:  2011 pressure\u003c|separator|\u003e\",\"url\":\"https://www.bbc.com/news/health-22029708\",\"favicon\":\"\"},{\"id\":\"123\",\"title\":\"Tamiflu: Millions wasted on flu drug, claims major report - BBC News\",\"description\":\"Apr 10, 2014 Â· The UK has spent Â£473m on Tamiflu, which is stockpiled by governments globally to prepare for flu pandemics. The Cochrane Collaboration,Â ...\",\"url\":\"https://www.bbc.com/news/health-26954482\",\"favicon\":\"\"},{\"id\":\"124\",\"title\":\"Government to combat flu outbreaks by removing red tape - GOV.UK\",\"description\":\"Sep 1, 2025 Â· Specifically this change will allow oseltamivir (TamifluÂ®) and zanamivir (RelenzaÂ®) to be prescribed and dispensed outside the flu season.Missing:  shortages guidelines\",\"url\":\"https://www.gov.uk/government/news/government-to-combat-flu-outbreaks-by-removing-red-tape\",\"favicon\":\"\"},{\"id\":\"125\",\"title\":\"Antiviral Chemotherapy in Avian Medicineâ€”A Review - PMC - NIH\",\"description\":\"Apr 12, 2024 Â· Another study confirmed that oseltamivir reduces the replication of low pathogenic AIV, significantly in chickens and completely in domesticÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11054683/\",\"favicon\":\"\"},{\"id\":\"126\",\"title\":\"Oseltamivir reduces transmission, morbidity, and mortality of highly ...\",\"description\":\"Treatment with systemically active oseltamivir limits to a large extent a severe outcome and chicken-to-chicken transmission of HPAI virus.\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0531513104000214\",\"favicon\":\"\"},{\"id\":\"127\",\"title\":\"Neuraminidase reassortment and oseltamivir resistance in clade 2.3 ...\",\"description\":\"In agreement with previous findings, A/Chicken/BC/FAV-0289-3/2024|H5N1 shows a 161.4-fold increase in oseltamivir half-maximal inhibitory concentration (IC50)Â ...\",\"url\":\"https://www.tandfonline.com/doi/full/10.1080/22221751.2025.2469643\",\"favicon\":\"\"},{\"id\":\"128\",\"title\":\"Comparison of oseltamivir and Î±-galactosylceramide for reducing ...\",\"description\":\"Oct 19, 2022 Â· Virus shedding was significantly delayed and reduced in oseltamivir treated pigs (OS group) compared to mock treated pigs (MC group) (Figure 1).\",\"url\":\"https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2022.999507/full\",\"favicon\":\"\"},{\"id\":\"129\",\"title\":\"Evaluation of the bioavailability of a Tamiflu taste-masking pediatric ...\",\"description\":\"Jun 11, 2024 Â· Juvenile pigs were administered with either commercial Tamiflu or its taste-masking formulation and plasma samples were obtained from 0 to 48 h.\",\"url\":\"https://www.tandfonline.com/doi/abs/10.1080/17576180.2024.2352256\",\"favicon\":\"\"},{\"id\":\"130\",\"title\":\"New Animal Drugs; Adamantane and Neuraminidase Inhibitor Anti ...\",\"description\":\"Mar 22, 2006 Â· The Food and Drug Administration (FDA) is issuing an order prohibiting the extralabel use of anti-influenza adamantane and neuraminidase inhibitor drugs inÂ ...\",\"url\":\"https://www.federalregister.gov/documents/2006/03/22/06-2689/new-animal-drugs-adamantane-and-neuraminidase-inhibitor-anti-influenza-drugs-extralabel-animal-drug\",\"favicon\":\"\"},{\"id\":\"131\",\"title\":\"Overview of Antiviral Agents Used in Animals - Pharmacology\",\"description\":\"In 2006, the FDA prohibited the extralabel use of adamantanes and neuraminidase inhibitors in chickens, turkeys, and ducks because of concern about theÂ ...Missing:  ban | Show results with:ban\",\"url\":\"https://www.merckvetmanual.com/pharmacology/antiviral-agents/overview-of-antiviral-agents-used-in-animals\",\"favicon\":\"\"},{\"id\":\"132\",\"title\":\"Current antivirals likely less effective against severe infection ...\",\"description\":\"Mar 17, 2025 Â· Scientists at St. Jude Children's Research Hospital have found that frequently used antivirals do not work well against the H5N1 avian influenzaÂ ...\",\"url\":\"https://www.stjude.org/media-resources/news-releases/2025-medicine-science-news/current-antivirals-likely-less-effective-against-severe-infection-caused-by-bird-flu-in-cows-milk.html\",\"favicon\":\"\"},{\"id\":\"133\",\"title\":\"Comparison of Antiviral Agents for Seasonal Influenza Outcomes in ...\",\"description\":\"Aug 13, 2021 Â· Antiviral agents were associated with significantly greater efficacy than placebo in shortening the duration of influenza symptoms.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8363918/\",\"favicon\":\"\"},{\"id\":\"134\",\"title\":\"Inhaled Zanamivir vs Oral Oseltamivir to Prevent Influenza-related ...\",\"description\":\"Oct 12, 2022 Â· Inhaled zanamivir is not inferior to oral oseltamivir as outpatient treatment in preventing influenza-related hospitalization or death.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/35299245/\",\"favicon\":\"\"},{\"id\":\"135\",\"title\":\"Factors associated with non-persistence to oral and inhaled antiviral ...\",\"description\":\"Jul 10, 2017 Â· We aimed to evaluate and compare non-adherence to oral and inhaled antiviral therapies prescribed of a randomised clinical trial inÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC5734282/\",\"favicon\":\"\"},{\"id\":\"136\",\"title\":\"Comparison of Antiviral Agents for Seasonal Influenza Outcomes in ...\",\"description\":\"Aug 13, 2021 Â· The most common adverse effects of oseltamivir are nausea and vomiting; zanamivir may cause bronchospasm; and peramivir may cause diarrhea.\",\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782995\",\"favicon\":\"\"},{\"id\":\"137\",\"title\":\"In hospitalized patients with influenza, oseltamivir or peramivir may ...\",\"description\":\"Dec 3, 2024 Â· The network meta-analysis showed that oseltamivir and peramivir vs. placebo or standard care each reduced duration of hospitalization inÂ ...\",\"url\":\"https://www.acpjournals.org/doi/10.7326/ANNALS-24-03198-JC\",\"favicon\":\"\"},{\"id\":\"138\",\"title\":\"Comparison of Efficacy and Safety of Baloxavir and Oseltamivir in ...\",\"description\":\"Oct 12, 2024 Â· The analysis revealed that baloxavir marboxil significantly reduced the duration of fever compared to oseltamivir (mean difference: -13.49 hoursÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/39529764/\",\"favicon\":\"\"},{\"id\":\"139\",\"title\":\"Comparison of the Effectiveness of Baloxavir and Oseltamivir ... - NIH\",\"description\":\"Aug 27, 2024 Â· The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13â€“5.43).\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11347862/\",\"favicon\":\"\"},{\"id\":\"140\",\"title\":\"Modeling Influenza Antiviral Strategies: Reducing Burden and ...\",\"description\":\"Oct 17, 2025 Â· Comparative evaluation of oseltamivir, baloxavir, and combination antiviral treatment strategies for seasonal influenza ... season/2023-2024.html.\",\"url\":\"https://academic.oup.com/jid/article/232/Supplement_3/S299/8287909\",\"favicon\":\"\"},{\"id\":\"141\",\"title\":\"Comparing Oral Antiviral Agents for Seasonal Influenza\",\"description\":\"Dec 17, 2021 Â· As evidenced by this study, oseltamivir has been proven safe even at doses much higher than that currently indicated for influenza treatment orÂ ...\",\"url\":\"https://www.uspharmacist.com/article/comparing-oral-antiviral-agents-for-seasonal-influenza\",\"favicon\":\"\"},{\"id\":\"142\",\"title\":\"Antiviral Recommendations for the 2022â€“2023 Influenza Season\",\"description\":\"Dec 16, 2022 Â· The CDC recommends the use of four FDA-approved antiviral drugs to treat influenza: oseltamivir, zanamivir, peramivir, and baloxavir marboxil.\",\"url\":\"https://www.uspharmacist.com/article/antiviral-recommendations-for-the-2022-2023-influenza-season\",\"favicon\":\"\"}],\"images\":[{\"id\":\"754cc79aaf88\",\"caption\":\"Oseltamivir chemical structure\",\"url\":\"./_assets_/Oseltamivir.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"2922e46c4803\",\"caption\":\"H1N1 virus\",\"url\":\"./_assets_/H1N1_navbox.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Oseltamivir\",\"title\":\"Oseltamivir\",\"content\":\"$1f\",\"description\":\"Oseltamivir\\n\\nOseltamivir chemical structure \\nOseltamivir is an oral antiviral prodrug indicated for the treatment of acute uncomplicated influenza A and B infections in patients two weeks of age and...\",\"metadata\":{\"categories\":[\"Tamiflu\"],\"lastModified\":\"1761585937\",\"contentLength\":\"63422\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"182573\",\"recentViews\":\"182573\",\"dailyAvgViews\":6085.7666015625,\"qualityScore\":1,\"lastViewed\":\"1761882182\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761882182073,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Oseltamivir\"],\"queryHash\":\"[\\\"page\\\",\\\"Oseltamivir\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Oseltamivir\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Oseltamivir is an oral antiviral prodrug indicated for the treatment of acute uncomplicated influenza A and B infections in patients two weeks of age and older who have been symptomatic for no more than two days, as well as for post-exposure prophylaxis in individuals one year and older. Developed by Gilead Sciences and marketed by Roche under the brand name Tamiflu, it functions as a neuraminidase inhibitor; after hydrolysis in the liver to its active carboxylate metabolite, this compound...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Tamiflu\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Oseltamivir\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Oseltamivir\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Oseltamivir is an oral antiviral prodrug indicated for the treatment of acute uncomplicated influenza A and B infections in patients two weeks of age and older who have been symptomatic for no more than two days, as well as for post-exposure prophylaxis in individuals one year and older. Developed by Gilead Sciences and marketed by Roche under the brand name Tamiflu, it functions as a neuraminidase inhibitor; after hydrolysis in the liver to its active carboxylate metabolite, this compound...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Oseltamivir\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Oseltamivir\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:45.937Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Oseltamivir\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Oseltamivir is an oral antiviral prodrug indicated for the treatment of acute uncomplicated influenza A and B infections in patients two weeks of age and older who have been symptomatic for no more than two days, as well as for post-exposure prophylaxis in individuals one year and older. Developed by Gilead Sciences and marketed by Roche under the brand name Tamiflu, it functions as a neuraminidase inhibitor; after hydrolysis in the liver to its active carboxylate metabolite, this compound...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="NWU1ODg4NzEtNjhjNS00Y2FiLTk4OGEtMGY4ZGJhOGJlZDE3">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Oseltamivir\"}]}]\n"])</script></body></html>